<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi Pharm J</journal-id><journal-id journal-id-type="iso-abbrev">Saudi Pharm J</journal-id><journal-id journal-id-type="pmc-domain-id">2116</journal-id><journal-id journal-id-type="pmc-domain">saudipharmj</journal-id><journal-title-group><journal-title>Saudi Pharmaceutical Journal : SPJ</journal-title></journal-title-group><issn pub-type="ppub">1319-0164</issn><issn pub-type="epub">2213-7475</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10172599</article-id><article-id pub-id-type="pmcid-ver">PMC10172599.1</article-id><article-id pub-id-type="pmcaid">10172599</article-id><article-id pub-id-type="pmcaiid">10172599</article-id><article-id pub-id-type="pmid">37181145</article-id><article-id pub-id-type="doi">10.1016/j.jsps.2023.03.016</article-id><article-id pub-id-type="pii">S1319-0164(23)00074-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Virosome: An engineered virus for vaccine delivery</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Ali</surname><given-names initials="H">Hasan</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Akbar</surname><given-names initials="M">Md.</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Iqbal</surname><given-names initials="B">Babar</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Ali</surname><given-names initials="F">Faraat</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Sharma</surname><given-names initials="NK">Neeraj Kant</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au030"><name name-style="western"><surname>Kumar</surname><given-names initials="N">Nitin</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au035"><name name-style="western"><surname>Najmi</surname><given-names initials="A">Asim</given-names></name><email>anajmi@jazanu.edu.sa</email><xref rid="af025" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au040"><name name-style="western"><surname>Albratty</surname><given-names initials="M">Mohammed</given-names></name><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au045"><name name-style="western"><surname>Alhazmi</surname><given-names initials="HA">Hassan A.</given-names></name><xref rid="af025" ref-type="aff">e</xref><xref rid="af030" ref-type="aff">f</xref><xref rid="af035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au050"><name name-style="western"><surname>Madkhali</surname><given-names initials="OA">Osama A.</given-names></name><xref rid="af040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au055"><name name-style="western"><surname>Zoghebi</surname><given-names initials="K">Khalid</given-names></name><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au060"><name name-style="western"><surname>Alam</surname><given-names initials="MS">Md Shamsher</given-names></name><email>mosalam@jazanu.edu.sa</email><xref rid="af025" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005"><label>a</label>Department of Pharmacy, Meerut Institute of Technology, National Highway-58, Meerut 250103, Uttar Pradesh, India</aff><aff id="af010"><label>b</label>School of Pharmacy, Al-Karim University, Katihar, Bihar 854106, India</aff><aff id="af015"><label>c</label>Formulation and Development, Unicure India Ltd Noida, Uttar Pradesh, India</aff><aff id="af020"><label>d</label>Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Kr&#225;lov&#233;, Charles University, Akademika Heyrovsk&#233;ho 1203, Hradec Kr&#225;lov&#233; 500 05, Czech Republic</aff><aff id="af025"><label>e</label>Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia</aff><aff id="af030"><label>f</label>Substance Abuse and Toxicology Research Centre, Jazan University, P. Box No. 114, Jazan, Saudi Arabia</aff><aff id="af035"><label>g</label>Medical Research Center, Jazan University, Jazan, Saudi Arabia</aff><aff id="af040"><label>h</label>Department of Pharmaceutics, College of Pharmacy, Jazan University, P. Box No. 114, Jazan, Saudi Arabia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>anajmi@jazanu.edu.sa</email><email>mosalam@jazanu.edu.sa</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>31</day><month>3</month><year>2023</year></pub-date><volume>31</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">435527</issue-id><fpage>752</fpage><lpage>764</lpage><history><date date-type="received"><day>4</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>22</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>12</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-15 07:26:05.903"><day>15</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Author(s)</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab005"><p><bold>The</bold> purpose of immunization is the effective cellular and humoral immune response against antigens. Several studies on novel vaccin<bold>e</bold> delivery approaches such as micro-particles, liposomes &amp; nanoparticles, etc<bold>.</bold> against infectious diseases have been investigated so far. In contrast to the conventional approaches in vaccin<bold>e</bold> development, a virosome<bold>s-b</bold>ased vaccine represent<bold>s</bold> the next generation in the field of immunization because of its balance betwee<bold>n e</bold>fficacy and tolerability by virtue of <bold>its</bold> mechanism of immune instigation. <bold>The</bold> versatility of virosomes as a vaccine adjuvant, <bold>and</bold> delivery vehicle of molecules of different nature, such as peptides, nucleic acids, <bold>and</bold> proteins, as well as provide an insight into the prospect of drug targeting using virosomes. This article focuses on the basics of virosomes, structure, composition formulation and development, advantages, interplay with the immune system, current clinical status, different patents highlighting the applications of virosomes <bold>and their status</bold>, recent advances<bold>,</bold> and research associated with virosomes, the efficacy, safety, and tolerability of virosomes based vaccines and <bold>the</bold> future prospective.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Virosome</kwd><kwd>Vaccine</kwd><kwd>Immunization</kwd><kwd>Adjuvant</kwd><kwd>Liposome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">A vaccine is a pharmaceutical technique that tempts an immunologically intervened fight, primarily to an infection, secondarily to other noninfectious diseases <bold>(</bold><xref rid="b0230" ref-type="bibr">Griffin, 2002</xref>, <xref rid="b0355" ref-type="bibr">Medzhitov and Janeway, 1997</xref><bold>).</bold> These are generally prepared of live but attenuated or killed microorganisms or subunits of microorganisms such as genetic materials and antigenic peptides of pathogenic microorganisms. However, subunit vaccines are remarkably selective and very precise in interacting with antibodies, but frequently ineffective to exhibit such reactions in the conditions like <bold>a</bold> minor change in the epitopic identification center of antibody and are poorly immunogenic <bold>(</bold><xref rid="b0470" ref-type="bibr">Shi et al., 2005</xref>, <xref rid="b0340" ref-type="bibr">Liu, 2011</xref>, <xref rid="b0040" ref-type="bibr">Baghban and Mahmoodi, 2022</xref><bold>)</bold>. Subunits of the causative pathogen microorganism like carbohydrates, proteins, DNA, <bold>and</bold> RNA, can be explored for generating selective, precise, strong, and prolonged immune reactions (<xref rid="b0470" ref-type="bibr">Shi et al., 2005</xref>, <xref rid="b0340" ref-type="bibr">Liu, 2011</xref>, <xref rid="b0040" ref-type="bibr">Baghban and Mahmoodi, 2022</xref>, <xref rid="b0440" ref-type="bibr">Prasad et al., 2011</xref>, <xref rid="b0435" ref-type="bibr">Praetorius and Mandal, 2007</xref>, <xref rid="b0195" ref-type="bibr">Fifis et al., 2004</xref><bold>).</bold></p><p id="p0010">To temp<bold>t i</bold>mmunity effectively, these vaccines need therapeutic potentiation with some factors, called as adjuvants. Generally, adjuvants are supposed to act <bold>by</bold> forming a complex with antigens to be inoculated, from which immunogens are gradually liberated <bold>(</bold><xref rid="b0450" ref-type="bibr">Saroja et al., 2011</xref><bold>)</bold>.<list list-type="simple" id="l0005"><list-item id="o0005"><label>&#8226;</label><p id="p0015"><italic toggle="yes">Vaccine delivery systems</italic> such as emulsions, liposomes, microparticles, immune-stimulating complexes (ISCOMs,) etc. <bold>(</bold><xref rid="b0450" ref-type="bibr">Saroja et al., 2011</xref><bold>)</bold>.</p></list-item><list-item id="o0010"><label>&#8226;</label><p id="p0020"><italic toggle="yes">Immunostimulatory adjutants:</italic> Intact molecular arrays of pathogenic microorganisms instigat<bold>e i</bold>mmunity, as they are recognized by Tol<bold>l-l</bold>ike receptor (TLR) receptors, pattern recognition receptors, found generally on B-cells, dendritic cells (DC) of mammals (e.g., unmethylated CpG containing DNA) <bold>(</bold><xref rid="b0450" ref-type="bibr">Saroja et al., 2011</xref><bold>)</bold>.</p></list-item></list></p><p id="p0025">Adjuvants augment the immuno-excitatory properties of antigens but remain non-immunogenic, biodegradable, and nontoxic by themselves <bold>(</bold><xref rid="b0450" ref-type="bibr">Saroja et al., 2011</xref><bold>)</bold>.</p><p id="p0030">As an innovative technique, simple biologically inactive nanocarriers capable to cater strong protection because of a single dos<bold>e</bold> can be advantageous for various applications <bold>(</bold><xref rid="b0385" ref-type="bibr">Mohanraj et al., 2010</xref><bold>)</bold>. These nanomaterials can be of natural and synthetic origin. <bold>Nanocarriers</bold> have equally been employed for the development of vaccines against pathological <bold>microorganisms (</bold><xref rid="b0115" ref-type="bibr">Champion et al., 2009</xref>, <xref rid="b0475" ref-type="bibr">Smith et al., 2011</xref><bold>)</bold>. Typically, nanocarriers are the particulate system, whose size ranges from 0.1&#160;nm to 100&#160;nm in diameter <bold>(</bold><xref rid="b0420" ref-type="bibr">Ozkan, 2004</xref><bold>)</bold>. Numerous types of nanomaterial have been utilized for the manufacture and synthesis of nanovaccines based on natural and synthetic origin. Virus-like particles (VLP), bacterial spores, nanobacteria, bacteriophages, proteosomes, liposomes, exosomes, nanoparticle-based nanobeads<bold>,</bold> etc. are salient examples of nanocarriers that are explored as promising nanocarriers for vaccine delivery <bold>(</bold><xref rid="b0115" ref-type="bibr">Champion et al., 2009</xref>, <xref rid="b0475" ref-type="bibr">Smith et al., 2011</xref>, <xref rid="b0290" ref-type="bibr">Jain, 2008</xref><bold>)</bold>.</p><p id="p0035">Technology based on shells of viruses that is virosom<bold>e</bold> offers a new smart carrier system to ward off the limitations associated with conventional vaccine delivery systems. Fundamentally, virosomes were manufactured from liposomes by uniting viral envelop<bold>e</bold> proteins <bold>that</bold> fuse with liposomes <bold>(</bold><xref rid="b0465" ref-type="bibr">Sharma and Yasir, 2010</xref><bold>)</bold>. Like viruses, virosomes have not the capacity to reproduce but basically, they are pure fusogenic shells <bold>(</bold><xref rid="b0345" ref-type="bibr">Ludwig and Wagner, 2007</xref><bold>)</bold>. Because of the membrane-fusion and receptor-binding features, virosomal glycoproteins can be conserved, and hence virosomes are used as an active targeting transport carrier for <bold>the</bold> cellular delivery of therapeutic molecules <bold>(</bold><xref rid="b0105" ref-type="bibr">Canal et al., 2011</xref><bold>)</bold>. Mitigation and management of infections and active precise immunotherapy for cancers often need the stimulation of an effective immune response, can also be accomplished after utilizing virosom<bold>e-b</bold>ased delivery vehicles transporting various types of antigens, for instance<bold>,</bold> proteins, peptides, oligonucleotides, plasmids, virions<bold>,</bold> etc. <bold>(</bold><xref rid="b0300" ref-type="bibr">Kaneda, 2000</xref><bold>)</bold>. A salient characteristic of virosomal <bold>carriers</bold> is that during <bold>the</bold> reconstitution of virosomes, several therapeutic agents can be anchored either on the membrane of virosomes or in the hydrophilic interior, like liposomes. Various antigens having small proteins have also been covalently anchored with virosomal envelopes. For this objective, a phospholipid, phosphatidylethanolamine (PE) is modified with a conjugator, permitting the covalent conjugation of proteins, most likely through a disulfide bond. However, water-soluble therapeutic agents can be entrapped inside the hydrophilic core of the shell, this can be utilized to deliver the content inside the cell by chimeric virosomes which further improves the high entrapment efficiency of the therapeutic agent with the receptor-mediated engulfment and the fusogenic characteristics of virosomes <bold>(</bold><xref rid="b0300" ref-type="bibr">Kaneda, 2000</xref>, <xref rid="b0285" ref-type="bibr">Hug and Sleight, 1994</xref><bold>)</bold>. This novel technique results in about 30 times surge in the quantity of encapsulated water-soluble peptides as compared to the conventional manufacturing methods. Moreover, they can be employed as an appropriate delivery system for RNA and DNA because these fusogenic shells imitate a virus. Also, virosomes exhibit adjuvant features, which is considered as an important property for stimulation of better immune response. <bold>The a</bold>djuvant nature of virosomes has previously been confirmed by licensed vaccines against influenza viz. Invivac<bold>&#174;</bold> (Solvay Pharmaceuticals), Inflexal<bold>&#174; V</bold> (Berna Biotech), and hepatitis A, Epaxal<bold>&#174;</bold> (Berna Biotech) which possesses the strong immunogenic potential with improved safety and biological properties of a virus-like particle <bold>(</bold><xref rid="b0285" ref-type="bibr">Hug and Sleight, 1994</xref>, <xref rid="b0010" ref-type="bibr">Amacker et al., 2005</xref>, <xref rid="b0135" ref-type="bibr">Cusi, 2006</xref><bold>).</bold> The present review discusses the basics of virosomes, structure and chemical composition<bold>,</bold> mechanistic pathway, advantages, their method of preparation, clinical and IPR status comprehensively, and also provide<bold>s</bold> an insight into the potential applications as vaccine carrier and targeting systems using virosomes. Furthermore, the different patents highlighting the applications of virosomes &amp; future <bold>prospects</bold> of it have also been discussed in the present review.</p></sec><sec id="s0010"><label>2</label><title>Virosomes</title><sec id="s0015"><label>2.1</label><title>Structure and composition of virosomes</title><p id="p0040">In context of lipid composition virosomes cater the same adaptability as liposomes, additionally virosomes contain membrane proteins, either derived from <bold>the</bold> virus itself or produced from recombinant technology <bold>(</bold><xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref><bold>)</bold>. Ultrastructurally, virosomes are unilamellar and spherical reconstituted viral vesicles, which comprises of membrane lipids and viral spike proteins on the surface, however without genetic material, with a mean diameter of about 150&#160;nm <bold>(</bold><xref rid="f0005" ref-type="fig">Fig. 1</xref><bold>)</bold>. The exterior of the virosome looks like an intact virus, with peplomer proteins<bold>,</bold> extended out from the membrane <bold>(</bold><xref rid="b0095" ref-type="bibr">Bungener et al., 2002</xref>, <xref rid="b0370" ref-type="bibr">Mischler and Metcalfe, 2002</xref>, <xref rid="b0090" ref-type="bibr">Bungener et al., 2005</xref><bold>)</bold>. The chief component of virosomes comprises of naturally occurring phospholipids mainly phosphatidylcholine. Only phosphatidylcholine is responsible for about 70% of the structure of the virosomes. The rest 30% of membrane constituents are consists of envelope phospholipids produced from virus, provide haemagglutinin (HA) and neuraminidase (NA) glycoproteins (<xref rid="b0285" ref-type="bibr">Hug and Sleight, 1994</xref>, <xref rid="b0010" ref-type="bibr">Amacker et al., 2005</xref>, <xref rid="b0135" ref-type="bibr">Cusi, 2006</xref>, <xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref>, <xref rid="b0095" ref-type="bibr">Bungener et al., 2002</xref>, <xref rid="b0370" ref-type="bibr">Mischler and Metcalfe, 2002</xref>, <xref rid="b0090" ref-type="bibr">Bungener et al., 2005</xref>, <xref rid="b0265" ref-type="bibr">Huckriede et al., 2003a</xref><bold>)</bold>. Fundamentally virosomes are, reconstituted hollow virus envelopes, which lacks genetic material, hence, not able to multiply like original pathogenic virus <bold>(</bold><xref rid="b0345" ref-type="bibr">Ludwig and Wagner, 2007</xref><bold>)</bold>. Unlike liposomes, virosomes comprises of purposeful glycoproteins hemagglutinin (HA) and neuraminidase (NA) <bold>embedded</bold> in the virus membrane <bold>(</bold><xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref>, <xref rid="b0095" ref-type="bibr">Bungener et al., 2002</xref>, <xref rid="b0370" ref-type="bibr">Mischler and Metcalfe, 2002</xref>, <xref rid="b0090" ref-type="bibr">Bungener et al., 2005</xref><bold>)</bold>. Exceptional <bold>characteristics</bold> of virosomes are partly related to the occurrence of immunologically active HA glycoprotein embedded in their membrane. Haemagglutinin glycoprotein not only ensure<bold>s</bold> the homogeneity and structural stability <bold>of</bold> virosome but also considerably potentiate the immune-stimulatory properties of virosomal particles, which are obviously different from that of other proteoliposomal and liposomal delivery systems. Fundamentally, HA is consisting of two protein regions those are developed after translational cleavage of HA into two subunits, that is HA1 and HA2, both remain in contact with a disulfide bond <bold>(</bold><xref rid="b0180" ref-type="bibr">Durrer et al., 1996</xref>, <xref rid="b0240" ref-type="bibr">Han et al., 2001</xref><bold>)</bold>. The HA1 subunit is consist of a globular head which possesses a receptor binding area that facilitate the attachment of virosomes to various sialic acid residues present on APCs surface <bold>(</bold><xref rid="b0460" ref-type="bibr">Schoen et al., 1996</xref>, <xref rid="b0235" ref-type="bibr">G&#252;nther-Ausborn et al., 2000</xref><bold>)</bold>. Whereas HA2 subunit has an N-terminal fusion protein and is embedded in the virosomal membrane. At approximately pH 7, HA1 subunit restrict<bold>s</bold> the HA2 subunit in a metastable state though in the inactive condition, where the fusion peptides are controlled by a complex of hydrogen bonds <bold>(</bold><xref rid="b0255" ref-type="bibr">Hernandez et al., 1996</xref><bold>).</bold> Conformational transformation of the HA, <bold>which</bold> exposes out hydrophobic regions of HA2 and instigate<bold>s</bold> the fusion of virosomes with the target cell membrane, after a change in the pH from neutral to acidic. At the time of influenza viral infection, this type of fusion phenomenon happens between the endosomal and viral membranes, which eventually mark in the liberation of the genetic material into the cytoplasm of the target cells. In the <italic toggle="yes">in vitro</italic> environment, without the presence of target cell, HA is generally deactivated in acidic milieu (about pH 5), at 37&#160;&#176;C temperature, hence, its fusogenicity is no more <bold>(</bold><xref rid="b0540" ref-type="bibr">Weber et al., 1994</xref><bold>)</bold>. Another glycoprotein found on the virosomal surface, is the NA, an enzyme consisted of four subunits (tetramer) that linked to the membrane hydrophobically, through a stem. The enzymatic loci are present in the subunit head region. Furthermore, <bold>the</bold> action of NA induces the splitting of NAM (sialic acid) from bound sugar residues <bold>(</bold><xref rid="b0310" ref-type="bibr">Kim et al., 1999</xref><bold>)</bold><fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Electron micrographs of empty virosome (A), and OVA-loaded virosome (B) <bold>(</bold><xref rid="b0095" ref-type="bibr">Bungener et al., 2002</xref><bold>).</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="s0020"><label>2.2</label><title>Molecular interaction and mechanistic pathway of virosomes</title><p id="p0045">The supposed pathway of internalization, intracellular intrusion of virosomes and Ag encapsulated with APC are depicted in <xref rid="f0010" ref-type="fig">Fig. 2</xref><bold>.</bold> Like the live virus, virosomes bind to sialic acid containing receptors on APCs, for instance, DC <bold>(</bold><xref rid="b0275" ref-type="bibr">Huckriede et al., 2003b</xref><bold>).</bold> Subsequently, virosomes with the aid of recepto<bold>r-f</bold>acilitated endocytosis, enter into the cell. In endosome, acidic pH stimulates fusion process between virosome and endosomal membrane following the release of encapsulated Ag into the cytosol. Antigen, entrapped in <bold>the</bold> internal environment of virosomes, can therefore, enter the conventional major histocompatibility complex (MHC) class I conduit, which is effective in bringing on cytotoxic T lymphocytes (CTL) responses. Nonetheless, all virosomal carriers are unlikely to fuse with the endosomal membrane; some virosomes are unavoidable from endosomal pathway. Finally, A<bold>g-e</bold>ncapsulated virosomes continue their presentation in the endosomal/lysosomal conduit, causing the degradation of the peptides or proteins. The peptides generated are manifested in the milieu of MHC class II molecules. Like the intact parental virus, virosomal carriers transport the entrapped Ag for the appearance in MHC class I and MHC class II, leading to the considerable stimulation of the immune system <bold>(</bold><xref rid="b0275" ref-type="bibr">Huckriede et al., 2003b</xref>, <xref rid="b0270" ref-type="bibr">Huckriede et al., 2005</xref>, <xref rid="b0250" ref-type="bibr">Hayashi et al., 1999</xref>, <xref rid="b0375" ref-type="bibr">Mizuguchi et al., 1996</xref>, <xref rid="b0075" ref-type="bibr">Bron et al., 1994</xref>, <xref rid="b0405" ref-type="bibr">Nakanishi et al., 2000</xref><bold>)</bold>. The subunit A of diphtheria toxin (DTA), a membrane impermeabl<bold>e-m</bold>acromolecular endotoxin, could be internalized into the cell when DTA was conjugated with virosomes. Because DTA itself cannot&#160;enter&#160;the&#160;cells,&#160;it&#160;is non-toxic; on the other hand, upon cytosolic liberation assisted by virosomes, DTA is toxic to the cells through the stimulation of elongation factor 2 concerned with protein synthesis in the cell <bold>(</bold><xref rid="b0375" ref-type="bibr">Mizuguchi et al., 1996</xref>, <xref rid="b0075" ref-type="bibr">Bron et al., 1994</xref><bold>)</bold>. The bovine serum albumin (BSA) virosomal cellular delivery by the Sendai virus was also established using the confocal laser microscopic technique. BSA labeled with fluorescent dye was encapsulated in liposomes and virosomes. Then these virosomes and liposomes containing fluorescent labeled BSA were pulsed to the EL4 thymoma cells. Only cells treated with virosomes containing labeled BSA showed cytosolic staining, indicating the capacity of virosomes to vomit out the encapsulated contents inside the cells more efficiently <bold>(</bold><xref rid="b0250" ref-type="bibr">Hayashi et al., 1999</xref>, <xref rid="b0405" ref-type="bibr">Nakanishi et al., 2000</xref><bold>)</bold>. It has also been studied that <bold>the</bold> virosomal delivery system is considerably effective in the delivery of ovalbumin (OVA), a reference protein Ag; for MHC class I presentation by murine bone marro<bold>w-d</bold>erived DC. Moreover, virosomes induced a marked expression of co-stimulatory molecules on DC, such as MHC class I, MHC class II, CD40, CD80 (B7-1)<bold>,</bold> and CD86 (B7-2), intercellular adhesion molecule (ICAM-1) <bold>(</bold><xref rid="b0095" ref-type="bibr">Bungener et al., 2002</xref><bold>)</bold>. However, it has also been reported that the influenza virosomes cannot&#160;trigger&#160;the&#160;upregulation&#160;of co-stimulatory molecules expressed on the surface of <bold>plasmacytoid</bold> DC <bold>(</bold><xref rid="b0020" ref-type="bibr">Angel et al., 2007</xref><bold>)</bold>. <bold>Basically, plasmacytoid DCs are a distinctive subgroup of DCs specific in secreting of type I interferons in higher concentrations. Moreover, plasmacytoid DCs exhibit an important role in immunogenic action against viral infections; and have found also involved in the onset and development of a number of autoimmune reactions and inflammatory diseases (</bold><xref rid="b0560" ref-type="bibr">Ye et al., 2020</xref><bold>).</bold> This dissimilarity might come from the differences between experimental subject i.e., mouse and human DC. For illustration, mouse DC contain lectin-like receptors, which could sense the HA and NA, protein spikes, presenting on the virosomal surface <bold>(</bold><xref rid="b0100" ref-type="bibr">Cambi and Figdor, 2003</xref><bold>)</bold>. Till now, the upregulation of immunostimulatory signals activated by virosomes is not yet well explained. The virosomes synthesized from the native viruses, thus, might have the capacity to upregulate the expression of co-stimulatory molecules, which are needed to prime T cells. To efficiently prime specific T cells, the costimulatory molecules expression on DC and the secretion of Th1 <bold>(helper T cells Type 1)</bold> polarizing cytokines such as <bold>interferon-&#947;</bold> (IFN&#947;) or IL-12 are fundamental phenomenon in the triggering of T cells mediated immunity <bold>(</bold><xref rid="b0510" ref-type="bibr">Trombetta and Mellman, 2005</xref>, <xref rid="b0045" ref-type="bibr">Banchereau and Steinman, 1998</xref><bold>)</bold>.<fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Diagrammatic representation of the interplay of virosomes with the immune system <bold>(</bold><xref rid="b0275" ref-type="bibr">Huckriede et al., 2003b</xref><bold>).</bold></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0050">Cuzi et al. have investigated the possibility of enhancing the immunogenicity of a plasmid DNA encoding carcinoembryonic Ag (CEA) by c<bold>o-e</bold>ncapsulation of plasmid expressing CD40L, a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily of molecules, in influenza virosomes <bold>(</bold><xref rid="b9010" ref-type="bibr">Cusi et al., 2005</xref><bold>)</bold>. It is hypothesized that CD40L expression by transfected DC would interact with the CD40 on DC, which eventually enhances the specific T-<bold>cell</bold> priming ability. Bioconjugation of lipopolysaccharide (LPS), TLR2 and TLR4 ligand, into the lipid-bilayer of virosomes was a potent drive for murine B lymphocytes, which was 10 times more active than the free LPS <bold>(</bold><xref rid="b0175" ref-type="bibr">Dijkstra et al., 1996</xref><bold>)</bold>. This could offer an effective and new strategic platform for tumor immunotherapy. Though influenza virosomes signify a constructive vaccine delivery system for CTL initiation, there is a viewpoint that immunity induced against <bold>the</bold> influenza virus after subbing clinical infections or vaccination might impede the immunit<bold>y-s</bold>timulating effect of influenza virosomes. Though, antibody-dependent increase the neutralization of influenza A virus by the cells possessing Fc receptor was assessed by employing three immunogenic strains of influenza A virus viz. H1N1, H2N2 and H3N2. Sera acquired from the mice after the primary infestation of influenza virus strains viz. H1N1, H2N2, or H3N2, neutralized the virus of the same strain as well as sera enhanced the uptake of the virus across the strain. Sera obtained from H1N1 strai<bold>n-i</bold>nfested animals increased the neutralization of the homologous strain that is H1N1 as well as H2N2 (heterologous) strain. Remarkably, sera obtained from mice after the immunization with H2N2 strain increased the neutralization of all virus strains (H1N1, H2N2, or H3N2). Furthermore, sera obtained from the H3N2 infected mice enhanced the neutralization of the H3N2 (homologous) as well as H2N2 (heterologous) viruses. These outcomes suggested that strain cross-reactive, antibodies enhanced the neutralization of different strains of <bold>the</bold> influenza A virus. Antibodies to NA may cause the improved neutralization of viruses of a varied strain. N2-specific monoclonal antibodies enhanced the neutralization of both H2N2 and H3N2 strains of influenza virus <bold>(</bold><xref rid="b0500" ref-type="bibr">Tamura et al., 1994</xref><bold>)</bold>. This implies that antibodies that bind to the influenza virus increase the neutralization of the virus via Fc-receptor by APCs. Zurbriggen and Gluck have also demonstrated that mice and rabbits, pre-immunized with <bold>the</bold> influenza virus, enhanced the induction of immunogenicity against peptide antigen linked to the influenza virus <bold>(</bold><xref rid="b0570" ref-type="bibr">Zurbriggen and Gluck, 1999</xref><bold>)</bold>.</p></sec></sec><sec id="s0025"><label>3</label><title>Advantages of virosomal drug delivery</title><p id="p0055">Virosome contains many properties of nanoparticulate vaccine and drug delivery technology. Virosomes encompass the benefits of liposomes and polymeric nanoparticle systems and additionally overcoming the time-based and <italic toggle="yes">in vivo</italic> instability issues that is associated with the conventional as well as polymeric nanoparticles vaccine delivery approaches. However, virosomes have more analogy with respect to structure, composition, and formulation properties with liposomes <bold>(</bold><xref rid="b0300" ref-type="bibr">Kaneda, 2000</xref><bold>)</bold>. This particulate system has some special featur<bold>es</bold> and advantages over other vaccine delivery syste<bold>ms</bold>.<list list-type="simple" id="l0010"><list-item id="o0015"><label>&#8226;</label><p id="p0060">virosomal carriers are biocompatible, biodegradable, non-toxic, and hence safe <bold>(</bold><xref rid="b0270" ref-type="bibr">Huckriede et al., 2005</xref><bold>)</bold>.</p></list-item><list-item id="o0020"><label>&#8226;</label><p id="p0065">immunopotentiation, because of cellular internalization and the long circulatory effect <bold>(</bold><xref rid="b0265" ref-type="bibr">Huckriede et al., 2003a</xref><bold>).</bold></p></list-item><list-item id="o0025"><label>&#8226;</label><p id="p0070">applicable with almost all key therapeutic categories of drugs like peptides, proteins, nucleic acids, anticancer drugs <bold>(</bold><xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref><bold>).</bold></p></list-item><list-item id="o0030"><label>&#8226;</label><p id="p0075">allows delivery of therapeutic molecules inside the target cell <bold>(</bold><xref rid="b0085" ref-type="bibr">Bungener et al., 2006</xref><bold>)</bold>.</p></list-item><list-item id="o0035"><label>&#8226;</label><p id="p0080">efficient targeting of tumor (<xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref>, <xref rid="b0020" ref-type="bibr">Angel et al., 2007</xref>, <xref rid="b0085" ref-type="bibr">Bungener et al., 2006</xref><bold>).</bold></p></list-item><list-item id="o0040"><label>&#8226;</label><p id="p0085">no <bold>autoimmunogenicity</bold> or anaphylaxis <bold>(</bold><xref rid="b0225" ref-type="bibr">Gl&#252;ck et al., 1994</xref><bold>).</bold></p></list-item><list-item id="o0045"><label>&#8226;</label><p id="p0090">encourages fusogenic activity in the endosomal pathway <bold>(</bold><xref rid="b0025" ref-type="bibr">Arkema et al., 2000</xref><bold>)</bold>.</p></list-item><list-item id="o0050"><label>&#8226;</label><p id="p0095">industrial scale up-ability <bold>(</bold><xref rid="b0330" ref-type="bibr">Leroux-Roels et al., 2013</xref><bold>).</bold></p></list-item></list></p></sec><sec id="s0030"><label>4</label><title>Manufacturing of virosome</title><sec id="s0035"><label>4.1</label><title>Conventional method for the preparation of virosomes</title><p id="p0100">Biological products in common and vaccines in specific are highly complex, potent, and environment sensitive products. The important task is to establish a smooth, sturdy, economical and precise manufacturing process which can produce a specifically defined <bold>nanoparticle</bold>, multi-components structure for clinical use of virosome. The structure and composition of virosomes and liposomes is fundamentally identical. Both virosomes and liposomes are constructed of a phospholipid bilayer resulting <bold>in</bold> a sac-like structure, in which a core can be employed for delivering a drug molecule, peptide, protein, nucleic acid etc. to the target tissues. A fundamental issue related <bold>to</bold> the liposomal carrier is their speedy clearance by the reticuloendothelial system (RES) <bold>(</bold><xref rid="b0315" ref-type="bibr">Krishnamachari et al., 2011</xref><bold>)</bold>. Numerous alterations have been proposed by the scientific community to cope-up with these practical problems, important one is the making a film of PEGs on the surface of liposomes, which can assist the liposomal carriers to work as a stealth carrier, thus, avoiding clearance by RES and hence prolonging the circulation time <bold>(</bold><xref rid="b0030" ref-type="bibr">Babar et al., 2013</xref><bold>)</bold>. As it is evident that each component of the virosomal delivery system is synthesized separately and then subsequently assembled into virosomes (<xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref>). For this purpose, high-quality antibody response recombinant proteins, peptides, and other components are obtained from GMP-certified suppliers. Because neutralized virus employed for virosomal carrier preparation is the similar substance which is utilized for the marketed preparation of influenza vaccine. Commercially, it can be procured from influenza virus vaccine producers. Even today, almost all virosomal carriers-based vaccines tried in human subjects were manufactured with influenza virus cultured in embryonated chicken eggs <bold>(</bold><xref rid="b0550" ref-type="bibr">Widjaja et al., 2006</xref><bold>)</bold>. Though, virus developed on cell culture has been established equally useful for the development of virosomal carriers <bold>(</bold><xref rid="b0205" ref-type="bibr">Geerligs et al., 2008</xref><bold>).</bold> Reconstitution of envelopes of virus generally relies on solubilization of the viral envelopes with no<bold>n-d</bold>enaturing detergents such as Triton X-100 and Octaethylene glycol mono (n-dodecyl) ether (C12E8) followed by removal of viral nucleocapsid complexes (<xref rid="b0275" ref-type="bibr">Huckriede et al., 2003b</xref>, <xref rid="b0410" ref-type="bibr">Nunes-Correia et al., 2002</xref><bold>)</bold>. After solubilization of virus envelop<bold>e</bold>, inherent genetic material of the virus is separated out by ultracentrifugation technique. Virus membrane is reconstituted after <bold>the</bold> self-assembling phenomenon of <bold>a</bold> fragmented viral membrane composed of phospholipids and other transmembrane glycoproteins. As a result, these virosomes are then separated out from un-entrapped Ag by discontinuous sucrose density gradient ultracentrifugation (<xref rid="b0275" ref-type="bibr">Huckriede et al., 2003b</xref>)<bold>.</bold></p><p id="p0105">Other procedures for virosomal carrier production have also been discussed. For example, virosomes produced as per the procedure of Berna Biotech are termed &#8220;immunopotentiating reconstituted influenza virosomes (IRIV)&#8221; <bold>(</bold><xref rid="b0185" ref-type="bibr">Felnerova et al., 2004</xref>, <xref rid="b0270" ref-type="bibr">Huckriede et al., 2005</xref><bold>)</bold>. IRIV are prepared by the detergent solubilization technique as mentioned above, but with the addition of external phospholipids, reassembled when C12E8 is either separated by dialysis or adsorption onto a hydrophobic resin <bold>(</bold><xref rid="b0480" ref-type="bibr">Stegmann et al., 1987</xref><bold>)</bold>. <bold>The a</bold>ntigen of interest such as DNA, RNA or plasmid is coupled to lipid anchor. Lipids encompass phospholipids and cholesterol, phospholipids for instance, phosphatidylethanolamine, sphingomyelin, phosphatidylcholine, phosphatidylserine, dioleyldimethylammonium chloride (DODAC), dioleoyl-3-trimethylammonium-propane (DOTAP) etc. Antigen coupled with lipid load on virosomes and certain antibodies such as mAbs can also be anchored to it that bind to the surface proteins (epitopes) of specific type of cells <bold>(</bold><xref rid="b0055" ref-type="bibr">Bhattacharya and Mazumder, 2011</xref><bold>).</bold> After the addition of external phospholipids, a higher Ag encapsulation and homogeneous virosome particles can be obtained <bold>(</bold><xref rid="b0320" ref-type="bibr">Kushnir et al., 2012</xref><bold>)</bold>. However, these IRIV would have lower membrane glycoprotein densities because of the excess lipids added during reconstitution. As a result, virosomes with excess phospholipids added might result in a decreasing in cell binding and fusion activity of virosomes.</p><p id="p0110">Another approach for preparing virosomal vaccine delivery system has been proposed via fusing simple lipid vesicles (liposomes) containing antigen with <bold>ultraviolet</bold> (UV)-inactivated Sendai virus particles (<xref rid="b0480" ref-type="bibr">Stegmann et al., 1987</xref>, <xref rid="b0320" ref-type="bibr">Kushnir et al., 2012</xref>). In contrast to the influenza virosomes these virosomal carriers are prepared according to the method discussed above, contain the viral RNA. General manufacturing method can be employed to antigens such as recombinant protein, pathogen derived proteins, synthetic peptides, or carbohydrates. Batch processing step is followed in the production of immunological products. After extraction, the viral antigens are mixed with phospholipids and detergent. Afterwards the product obtained, was allowed to pass through different decontamination and sterilization steps. Generally, the virosomal formulation is dispersed in a buffered normal saline solution to get stable and safe final product <bold>(</bold><xref rid="b0110" ref-type="bibr">Carmona-Ribeiro, 2010</xref>, <xref rid="b0505" ref-type="bibr">Tofoli et al., 2011</xref><bold>).</bold> These purification and formulation steps make the virosome stable, safe, and effective for use. The production procedure of virosomal carrier is established at industrial scale with GMP specifications, as established by the continuous production of Epaxal&#174; and Inflexal &#174; V. The <italic toggle="yes">in vitro</italic> self-assembly of the virosomal carrier is accomplished at higher concentration and therefore, in a small volume, thus allowing for large scale production of up to 500,000 doses per run even in small facilities <bold>(</bold><xref rid="b0330" ref-type="bibr">Leroux-Roels et al., 2013</xref><bold>)</bold>.</p><p id="p0115">For characterization of the virosomal formulation, simple qualitative tests are carried out that are explicitly intended for viral proteins. Methods of analysis based on electron microscopy, generally, <bold>scanning electron microscopy (SEM)</bold> can be employed for the evaluation of the precise shape, texture, size, and structure of the virosomes. Characteristic evaluation of virosomes depends on the property of the material to be tested. Viral proteins are evaluated by comparatively versatile and straightforward procedures like sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE). Virosomes&#8217; fusogenic activity can be estimated employing the fluorescent resonance energy transfer (FRET) method <bold>(</bold><xref rid="b0165" ref-type="bibr">Deniger et al., 2006</xref>, <xref rid="b0390" ref-type="bibr">Moser et al., 2003</xref>, <xref rid="b0095" ref-type="bibr">Bungener et al., 2002</xref><bold>).</bold></p></sec><sec id="s0040"><label>4.2</label><title>Cell-free protein synthesis: A new approach for virosome preparation</title><p id="p0120">Generally, the influenza virus come into the cells via endocytotic mechanism arbitrated by the binding of sialic acid and HA1, consequently, HA2 get fused with the cell. Typically, traditional approaches for the manufacture of virosomes are based on influenza virus, which generally do not claim the membrane fusion features of influenza viruses, completely. Cell-free protein synthesis (CFPS), a novel protein expression technique, offers a practically feasible approach for the protein&#8217;s synthesis for virosomes. Generally, this technique does not require the involvement of surfactants, hence it hardly damage<bold>s</bold> the functional structure of the proteins. Additionally, this technique also encompasses easy manufacturing methods. Interestingly, it is a on<bold>e-s</bold>tep process where two phenomena i.e., protein synthesis and membrane integration are taking place simultaneously (<xref rid="f0015" ref-type="fig">Fig. 3</xref>) <bold>(</bold><xref rid="b0535" ref-type="bibr">Wang et al., 2022</xref><bold>)</bold>. The manufacturing method is briefly illustrated i<bold>n</bold>
<xref rid="f0020" ref-type="fig">Fig. 4</xref>.<fig id="f0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Diagrammatic illustration of cell-free protein synthesis (CFPS) <bold>(</bold><xref rid="b0535" ref-type="bibr">Wang et al., 2022</xref><bold>)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig><fig id="f0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Flow chart of process of synthesis of virosome using cell-free protein synthesis (CFPS) system.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0125">Konstanins et al. effectively produced a peptide along with <bold>a</bold> linking agent, cytoplasmic tail (HA-TMR-CT), an &#945;-helical secondary structure, and transmembrane region using <bold>the</bold> CFPS method of virosome production with enhanced yield <bold>(</bold><xref rid="b0365" ref-type="bibr">Mineev et al., 2013</xref><bold>)</bold>. HA2 virosomes were produced by employing a rabbit reticulocyte lysate system, study exhibited a pH-dependent fusogenic activity of the HA2 virosomes and showed an outstanding activity to deliver siRNA. MS2 bacteriophage coat protein by <italic toggle="yes">Escherichia coli</italic> cell-free protein <bold>was</bold> synthesized fruitfully <bold>(</bold><xref rid="b0080" ref-type="bibr">Bundy et al., 2008</xref><bold>).</bold> After recognition, <bold>the</bold> MS2 bacteriophage protein helps the exogenous RNA to encapsulate <bold>(</bold><xref rid="b0490" ref-type="bibr">Stockley et al., 1994</xref><bold>)</bold>. It has also been studied that the synthesis of virus-like particles (VLPs) as a carrier for exogenous RNA by employing MS2 bacteriophage protein <bold>(</bold><xref rid="b0425" ref-type="bibr">Pan et al., 2012</xref><bold>;</bold>
<xref rid="b0545" ref-type="bibr">Wei et al., 2009</xref><bold>;</bold>
<xref rid="b0495" ref-type="bibr">Sun et al.,2011</xref><bold>)</bold>. MS2 bacteriophage protein has also been used in the CFPS to synthesize virosomes as a siRNA carrier. A virus glycoprotein 64 (Gp64), is a protein expressed over the <italic toggle="yes">Baculovirus</italic> envelope with the capacity of CFPS and siRNA delivery. It has been studied that Gp64 exhibit a pH reliant membrane fusion feature, which was comparable to HA2. Gp64 induced membrane fusion was observed at acidic pH, generally less than 5.5 <bold>(</bold><xref rid="b0060" ref-type="bibr">Blissard and Wenz, 1992</xref><bold>).</bold> A glycoprotein, F, attributed to Sendai virus also exhibit the virosomes production by cell-free protein synthesis. Fusion (F) protein and hemagglutinin-neuraminidase (HN) are the two glycoproteins which are found on the virus envelop<bold>e</bold> of Sendai virus <bold>(</bold><xref rid="b0035" ref-type="bibr">Bagai and Sarkar, 1993</xref><bold>).</bold> Interestingly, glycoprotein, F, take part in the fusion process of Sendai virus with membrane of the target cell. However, scientists precisely isolated F and HN glycoprotein and investigated the role of F glycoprotein in the membrane fusion of the target cell and proved that whole F-glycoprotein is essential for this process <bold>(</bold><xref rid="b0380" ref-type="bibr">Mizuguchi et al., 1999</xref><bold>). Furthermore, i</bold>t was studied that virosomal carriers produced by incorporating F- glycoprotein into the phospholipids showed the capacity to instigate fusogenic property and gene delivery potential <bold>(</bold><xref rid="b0525" ref-type="bibr">Verma et al., 2005</xref><bold>).</bold></p><p id="p0130">Therefore, as compared to the conventional method of virosome synthesis, the CFPS method could warrant the accurate folding and precise alignment of the peptides implicated in the synthesis of virosomes and the functional and structural intactness of virosomes, which could b<bold>e e</bold>mphasized fo<bold>r f</bold>uture research. Furthermore, because of its noteworthy merits over traditional virosomes manufacturing method, CFPS, as a novel technology for the manufacturing of virosomes, will certainly encourag<bold>e n</bold>ew progress in virosomal technology, which will eventually serve as a cutting-edge nano-carrier technology to surmount the existing challenges in immunotherapy and gene delivery.</p></sec></sec><sec id="s0045"><label>5</label><title>Stimulation of cellular immunity using virosomal technique</title><p id="p0135">Generally, cytotoxic T lymphocytes (CTLs) are accountable for the neutralization of viru<bold>s-i</bold>nfested cells and therefore are responsible for the mitigation and cure from the viral infections <bold>(</bold><xref rid="b0485" ref-type="bibr">Stevenson and Doherty, 1998</xref><bold>)</bold>. CTLs specific to <bold>the</bold> influenza virus are primarily triggered by epitopes <bold>originating</bold> from proteins present inside the virus, for instance, matrix proteins and the nucleoproteins, in humans, whereas immunodominant epitopes are manifested mainly on the nucleoprotein, in mice <bold>(</bold><xref rid="b0430" ref-type="bibr">Parker and Gould, 1996</xref><bold>)</bold>. Though, physiologically significant CTL activity may be induced by other viral antigens like haemagglutinin. Generally, immunization with traditional vaccine does not induce substantial CTL activity, hence these vaccines are not better option as a carrier of antigens to the APC. Generally, subunit vaccines do not possess the significant CTL antigens, for instance, nucleoprotein an<bold>d m</bold>atrix protein. In this way, virosomal carriers unclutch the opportunity to deliver antigens across the cell membrane, that is direct to the cytosol for antigen presentation on MHC class I system and therefore may improve CTL activity with augmentation of antibody responses. Helper-T cells are of critical significance, specifically for triggering the activity of B cell. Helper-T cells are also important for the development of B cells and antibody class changing <bold>(</bold><xref rid="b0050" ref-type="bibr">Baumgarth, 2000</xref><bold>)</bold>. Furthermore, helper-T cells augment the cytokine production, where CTLs can develop. Therefore, vaccines must be capable of tempting strong helper-T cell reactions, a matter that is frequently ignored. Influenza infection characteristically tempts the helper-T cells mediated immune reaction which is described by the secretion of <bold>IFN</bold>&#947; as the main cytokine. Such type of helper-T cell reaction encourages the biosynthesis of antibodies of IgG2a in mice and IgG1 subclass in humans, and stimulates the CTLs development <bold>(</bold><xref rid="b0485" ref-type="bibr">Stevenson and Doherty, 1998</xref><bold>)</bold>.</p><p id="p0140">As a proof of concept, the virosomal carriers with an anchored peptide are found to conform a well-recognized CT<bold>L-s</bold>pecific nucleoprotein epitope, which can further improve the nucleoprotein-specific CTL reaction. It was investigated that mice vaccinated with the peptide-anchored virosomal carriers twice (with the <bold>2-week</bold> interval), from <bold>the</bold> intraperitoneal route of administration <bold>were</bold> found to exhibit augmented CTL reactions against the peptide. Even <bold>a</bold> small amount, as low as <bold>0.5&#160;&#956;</bold>g of virosome entrapped peptide was adequate to instigate a strong immune response like an intact infectious influenza virus<bold>.</bold> However, vaccination with even higher amount, as high as <bold>100&#160;&#956;</bold>g of free peptide did not exhibit CTL stimulation. Fusion process of <bold>the</bold> virosomal carrier was vital for <bold>the</bold> instigation of the immune reaction because fusio<bold>n-d</bold>isabled virosomal carrier were unsuccessful to produce a considerable CTL response <bold>(</bold><xref rid="b0025" ref-type="bibr">Arkema et al., 2000</xref><bold>)</bold>. It was observed <italic toggle="yes">in vitro</italic> that virosomal carriers are proficient <bold>the</bold> in delivery of ovalbumin (OVA) prototype antigen into the DC, thus tempting MHC class I antigen presentation of ovalbumin. It has also been studied <italic toggle="yes">in vivo</italic> that virosomal carriers are proficient in promptin<bold>g O</bold>V<bold>A-i</bold>nduced CTL responses (<xref rid="b0090" ref-type="bibr">Bungener et al., 2005</xref>)<bold>.</bold> Mice were vaccinated two times with an interval of <bold>a</bold> fortnight with <bold>2.5&#160;&#956;g</bold> of OVA in virosomal carriers through different vaccination routes. After a week of booster dose, OVA induced CTL activity was studied in the vaccinated mice spleen cells by utilizing OVA specific target cells in a <bold>Chromium-51 (51Cr)-release</bold> assay. <bold>This assay is&#160;generally employed for the specific and precise estimation of cytotoxicity of NK cell and CTLs (</bold><xref rid="b0305" ref-type="bibr">Karimi et al., 2014</xref><bold>).</bold> Employing MHC tetramer staining and <bold>IFN</bold>&#947;, effector cell populace triggered by vaccination of mice with OVA-containing virosomal carriers were evaluated by enzyme-linked immunosorbent spot (<bold>ELISPOT) assay</bold>. These findings exhibited that vaccination of mice with virosomal carriers having OVA proficiently primes and triggers CD8&#160;+&#160;T cells that are involved against the Kb-bound OVA epitope SIINFEKL, a well characterized protein. These cells show the capacity to lyse the target cells presenting the OVA peptide exhibit the potential of producing IFN&#947;. It was postulated that virosomal carrie<bold>r</bold> arbitrated CTL stimulation is fundamentally based on the transport of antigen encapsulated virosomal carriers into APC. To get new insights into the mechanistic pathway of virosomal carriers facilitated priming of CTL activity, mice were vaccinated with fusion active and fusion inactive OV<bold>A-c</bold>ontaining virosomes. It was observed that OVA specific CTL stimulation was more in the mice, immunized with fusion active OVA virosomes as compared to the one which is vaccinated with fusion inactive virosomes. Fusion inactivation of OVA virosomes caused a reduction in CTL activity to about half. Therefore, fusion activity of the virosomes <italic toggle="yes">in vivo</italic> is not crucial for stimulation of a CTL response, however, evidently useful for optimal CTL priming. The capacity of fusion inactive virosomal carriers to carry antigens for MHC class I presentation, is because of the escape of exogenous antigen from the APC endosomes, following the presentation of antigenic peptides by MHC class I molecules. These outcomes suggest that virosomal carriers are potential agents for CTL-inducing vaccines because of their capacity to carry entrapped antigens, <italic toggle="yes">in vivo</italic>, across the cell membrane to the cytosol of APC <bold>(</bold><xref rid="b0270" ref-type="bibr">Huckriede et al., 2005</xref><bold>)</bold>.</p><p id="p0145">Helper-T cells responses of subunit and virosom<bold>e-b</bold>ased influenza vaccines were studied after the vaccination of mice. After intramuscular administration, bot<bold>h v</bold>accines tempted influenza specific helper-T cells. After the instigation of immunity with influenza antigen, CTL acquired from the spleen of immunized mice yields IFN&#947; and IL-4 showing that immunization tepmted a balanced response (type 1 helper T cells vs type 2 helper T cells). Though, IFN&#947; yielding cells were considerably increased in number in the mice, immunized with virosomal vaccine in comparison with the mice vaccinated with <bold>the</bold> subunit vaccine <bold>(</bold><xref rid="b0270" ref-type="bibr">Huckriede et al., 2005</xref><bold>)</bold>. These findings suggest that the viral antigens presentation has a deep impact on the magnitude of immune response. As compared to the subunit vaccines, the helper-T cell response instigated by virosomal vaccines were more resembl<bold>e to</bold> that witnessed after the infectious viruses.</p></sec><sec id="s0050"><label>6</label><title>Clinical Status: Lab to bed side</title><p id="p0150">Over the last twenty years, a substantial number of clinical involvements of immunization with influenza vaccine in general, and influenza virosomes has been gathered. Epaxal&#174;, hepatitis A vaccine developed by Crucell was the first approved vaccine based on virosomes, for commercial applications <bold>(</bold><xref rid="b0015" ref-type="bibr">Ambrosch et al., 1997</xref><bold>)</bold>. In brief, Epaxal&#174; was composed of pathologically inactivated hepatitis A virus adsorbed onto the surface of already made influenza virosome <bold>(</bold><xref rid="b0220" ref-type="bibr">Gl&#252;ck and W&#228;lti, 2000</xref><bold>)</bold>. As compared to alum-adjuvanted products, hepatitis A virus vaccines based on virosomes attributed at almost equal immunogenicity, a substantial local tolerance, and the creation of long-term memory based on B cell was exhibited by various clinical studies <bold>(</bold><xref rid="b0065" ref-type="bibr">Bovier, 2008a</xref>, <xref rid="b0070" ref-type="bibr">Bovier, 2008b</xref>, <xref rid="b0245" ref-type="bibr">Hatz et al., 2011</xref><bold>)</bold>.</p><p id="p0155">Fundamentally, influenza vaccines are homologous to the influenza virosomes, wherein virus envelope proteins behave as the antigen of interest. Implementation of influenza virosomes as an antigen carrier, the immunogenic effects such as expanded CD4 and Helper-T lymphocytes associated with the presence of influenza envelop<bold>e</bold> proteins, are not considered as added adjuvant characteristics as they are closely associated with the antigen. A definite particle construction and the enhanced phospholipid amount differentiates influenza vaccines based on virosomal carriers from orthodox subunit vaccines. But, as compared to the adjuvanted vaccines of influenz<bold>a-l</bold>ike FluAd&#174;, <bold>and</bold> Inflexal&#174; V, a virosomal vaccine does not carry any other supplementary immuno-stimulatory constituents. Inflexal<bold>&#174;</bold> V is the only adjuvanted vaccine of influenza, which is useful for all age groups and exhibit<bold>s</bold> a notable immune response in immunocompromised and healthy children, adults, and <bold>the</bold> elderly <bold>(</bold><xref rid="b0260" ref-type="bibr">Herzog et al., 2009</xref><bold>).</bold> Nasal Flu, an influenza vaccine, administered through <bold>the</bold> intranasal route, contained the identical virosomes as Inflexal<bold>&#174;</bold> V, additionally, it is adjuvanted with <italic toggle="yes">E. coli</italic> (mucosal adjuvant). After the increased occurrences of Bell&#8217;s palsy in immunized individuals, it was withdrawn soon after the launch <bold>(</bold><xref rid="b0400" ref-type="bibr">Mutsch et al., 2004</xref><bold>).</bold> Probably these adverse events were produced by the hea<bold>t-l</bold>abile toxins (HLT), which was then established by identical observations in the clinical trials with the non-virosomal influenza vaccines adjuvanted with HLT, administered intranasally <bold>(</bold><xref rid="b0400" ref-type="bibr">Mutsch et al., 2004</xref>, <xref rid="b0335" ref-type="bibr">Lewis et al., 2009</xref><bold>)</bold>. Invivac&#174;, a virosom<bold>e-b</bold>ased trivalent seasonal influenza vaccine for i.m. administration, was launched in 2004 by Solvay Pharmaceuticals, remain<bold>s</bold> commercially accessible in the market for one season only <bold>(</bold><xref rid="b0160" ref-type="bibr">de Bruijn et al., 2007</xref>, <xref rid="b0150" ref-type="bibr">de Bruijn et al., 2004</xref>, <xref rid="b0155" ref-type="bibr">de Bruijn et al., 2006</xref><bold>).</bold></p></sec><sec id="s0055"><label>7</label><title>Vaccines in clinical development</title><p id="p0160">Virosomal carriers present an innovative and well-known, drug carrier system. Various virosomal products are presently available commercially to achieve the therapeutic, diagnostic, and prophylactic purposes. Virosomal vaccines can serve the purpose of immunization products by actively prompting an immune reaction. Correspondingly, they could be good candidates as an adjuvant. Owning the ability to deliver macromolecules like proteins, nucleic acids etc, virosomal carriers are perfect device to act as drug carrier systems. Virosomal drug carrier systems exhibit good pharmacokinetic properties, guaranteeing the effective and safe way to explore the therapeutic potential of a drug. The fusion capacity of the virosomal carriers differs with the amount of viral surface proteins. Furthermore, the batch processing and complex assay techniques are some limitations of virosomes. Therefore, efforts are required to be made in this setting to develop simple and easy assay methods. <bold>Addressing</bold> these concerns and troubleshooting them will guarantee the approval and availability of a greater number of biopharmaceuticals <bold>based on virosomes (</bold><xref rid="b0400" ref-type="bibr">Mutsch et al., 2004</xref>, <xref rid="b0335" ref-type="bibr">Lewis et al., 2009</xref>, <xref rid="b0160" ref-type="bibr">de Bruijn et al., 2007</xref>, <xref rid="b0150" ref-type="bibr">de Bruijn et al., 2004</xref>, <xref rid="b0155" ref-type="bibr">de Bruijn et al., 2006</xref><bold>)</bold>.</p><p id="p0165">A synthetic peptide (derived from <italic toggle="yes">Plasmodium falciparum)</italic> based vaccine of malaria was tested clinically. A clinical trial Phase I study with healthy children and adult subjects demonstrated <bold>a</bold> high degree of immunogenicity, excellent tolerability, and good safety. But in Phase II trial, a tardy and morphologically atypical parasite growth was observed <bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold>.</p><p id="p0170">A hepatitis C vaccine based on three peptides among which two peptides representing CTL epitopes, are entrapped in virosome, and the third peptide acting as a CD4 epitope are attached on the surface of virosome. It was formulated as a therapeutically active T-cell vaccine in order to treat chronic hepatitis C viral infections. Though, the vaccine was unsuccessful to trigger the expected T-cell response in the healthy subjects in the clinical trial (Phase I) <bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold>.</p><p id="p0175">An intramuscular and intravaginal freez<bold>e-d</bold>ried virosomal vaccine with membran<bold>e-a</bold>ttached <bold>recombinant Secreted aspartic peptidases (</bold>rtSap2<bold>)</bold> was synthesized for the treatment of recurrent vulvovaginal Candidiasis. It is exhibited by a membrane attached rtSap2, enzymatically inactive, recombinant, and an abridged form of the secreted protease Sap2. <bold>Fundamentally,</bold>&#160;<bold>Sap2 is an acidic hydrolases enzyme responsible for virulence factor in <italic toggle="yes">Candida</italic>. This enzyme help to provide the fungus with amino acids and able to degrade some selected host's proteins implicated in the immune response and induces host inflammatory cytokine synthesis.</bold> In a Phase I study both application routes were studied independently in healthy subjects. Intravaginal as well as intramuscular applications were reported safe, nontoxic, and hence well tolerated <bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref>, <xref rid="b0455" ref-type="bibr">Schaller et al., 2003</xref><bold>)</bold>.</p><p id="p0180">A target authenticated (established by Trastuzumab), <bold>a</bold> trivalent vaccine was designed to trigger the production of antibodies targeting <bold>the</bold> Her2/neu receptor, for the management of breast cancer. This vaccine is incorporated with three peptides derived from Her2/neu that were attached <bold>to</bold> the influenza virosomal surface <bold>(</bold><xref rid="b0555" ref-type="bibr">Wiedermann et al., 2010</xref><bold>)</bold>. Clinical trials related to virosome&#160;are&#160;summarized&#160;in <xref rid="t0005" ref-type="table">Table 1</xref><bold>.</bold><table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Clinical studies, types, and their status related to vaccine delivery through virosomes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Vaccine</bold></th><th colspan="1" rowspan="1"><bold>Type of study</bold></th><th colspan="1" rowspan="1"><bold>Phase</bold></th><th colspan="1" rowspan="1"><bold>Status</bold></th><th colspan="1" rowspan="1"><bold>NCT Number</bold></th><th colspan="1" rowspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Malaria</td><td colspan="1" rowspan="1">Double-blind randomized placebo controlled</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00513669">NCT00513669</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Hepatitis C</td><td colspan="1" rowspan="1">Single-blind randomized placebo Controlled</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00445419">NCT00445419</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Recurrent Vulvovaginal Candidiasis</td><td colspan="1" rowspan="1">Randomized Placebo Controlled</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01067131">NCT01067131</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Non-randomized, Open Label</td><td colspan="1" rowspan="1">Phase IV</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01457027">NCT01457027</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Hepatitis A</td><td colspan="1" rowspan="1">Randomised, Open, Controlled Study</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01307436">NCT01307436</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Hepatitis A</td><td colspan="1" rowspan="1">Open, Randomized, Controlled</td><td colspan="1" rowspan="1">Phase IV</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01349829">NCT01349829</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Open, Non-randomized Trial</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01349829">NCT01349829</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Open, Non-randomized Trial</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01631110">NCT01631110</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Hepatitis A</td><td colspan="1" rowspan="1">Open, Randomised, Controlled Study</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01405677">NCT01405677</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Randomised Double Blind Study</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00814229">NCT00814229</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Breast Cancer</td><td colspan="1" rowspan="1">Non-randomized, open</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0555" ref-type="bibr">Wiedermann et al., 2010</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">Randomised Double Blind Study</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01084343">NCT01084343</ext-link></td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0120" ref-type="bibr">ClinicalTrials.gov, 2022</xref><bold>)</bold></td></tr></tbody></table></table-wrap></p><p id="p0185">Because of the various pros and cons of non-virus and virus-based carriers, the notion of carrying siRNA employing <bold>a</bold> virosome delivery system has been studied in a pre-clinical setting. The virosomal carrier system with the prospects of siRNA delivery encompassing, different types of virus proteins employed to synthesize virosomes. The cell-free protein synthesis method could be a potential platform for the delivery <bold>of</bold> siRNA through virosomal drug carriers <bold>(</bold><xref rid="b0280" ref-type="bibr">Huckriede et al., 2007</xref><bold>).</bold></p><p id="p0190">Despite a number of advances in the area of immunization and vaccines, there is still a technological gap and challenges to develop a novel and effective for the treatment of ailments like AIDS, malaria, and tuberculosis. Moreover, some of the currently available immunization products have limitations like <bold>the</bold> inability to completely instigate the immune response, <italic toggle="yes">in vivo</italic> intactness issues, systemic toxicity, frequented dosing, and <italic toggle="yes">in vitro</italic> stability and preservation challenges. To troubleshoot the abovementioned problems nanotechnology <bold>has e</bold>merge<bold>d a</bold>s an important tool. Commonly, nanovaccine system is a novel type of vaccine employing nanoparticles (NPs) as a carrier system and as an adjuvant. Because the NPs and immunoge<bold>ns</bold> are of almost similar size, hence, the immune response can be induced considerably, resulting in a better outcome. Hence, nanovaccines encompass <italic toggle="yes">in vivo</italic> intactness, better immunity instigation, chances of frequented and booster dosing are rare, better <italic toggle="yes">in vitro</italic> stability, and the ability to target actively <bold>(</bold><xref rid="b0210" ref-type="bibr">Hayat et al., 2019</xref><bold>)</bold>. Some recently approved marketed nanovaccine products are discussed in <xref rid="t0010" ref-type="table">Table 2</xref>.<table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Clinically tested and recently approved COVID-19 nano-vaccines for human use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Pay-Load</bold></th><th colspan="1" rowspan="1"><bold>Brand Name</bold></th><th colspan="1" rowspan="1"><bold>Marketed By</bold></th><th colspan="1" rowspan="1"><bold>Year of approval</bold></th><th colspan="1" rowspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Nucleoside-modified mRNA</td><td colspan="1" rowspan="1">Spikevax</td><td colspan="1" rowspan="1">Pfizer-BioNTech</td><td colspan="1" rowspan="1">2022</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0520" ref-type="bibr">USFDA, 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">BNT162b2&#160;[mRNA]</td><td colspan="1" rowspan="1">Comirnaty</td><td colspan="1" rowspan="1">BioNTech-Pfzer</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0325" ref-type="bibr">Lamb, 2021</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Recombinant incompetent Ad26 vector</td><td colspan="1" rowspan="1">Janssen COVID-19 Vaccine</td><td colspan="1" rowspan="1">Johnson &amp; Johnson</td><td colspan="1" rowspan="1">2020</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0445" ref-type="bibr">Sa et al., 2022</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Adenovirus serotypes 5 and 26</td><td colspan="1" rowspan="1">Sputnik V</td><td colspan="1" rowspan="1">Gamaleya Research Institute of Epidemiology and Microbiology, Russia</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0360" ref-type="bibr">Mikule et al., 2021</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Recombinant human adenovirus 26 serotype</td><td colspan="1" rowspan="1">Sputnik Light</td><td colspan="1" rowspan="1">Gamaleya Research Institute of Epidemiology and Microbiology, Russia</td><td colspan="1" rowspan="1">2021</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0515" ref-type="bibr">Tukhvatulin etal., 2021</xref><bold>)</bold></td></tr></tbody></table></table-wrap></p><sec id="s0060"><label>7.1</label><title>Tolerability</title><p id="p0195">Presently available influenza vaccines on the market are effective and safe for treatment of influenza. However, there is still a requirement for influenza vaccines with better efficacy, in general and for geriatric patients. Currently, several techniques are being evolved so as to increase the safety and efficacy of influenza vaccines in geriatric patients and the patient population who exhibit weakened immune reactions to orthodox influenza vaccines. A well-known general characteristic, which was frequently established for the approved formulations, of all virosomal vaccines is their good tolerability <bold>(</bold><xref rid="b0260" ref-type="bibr">Herzog et al., 2009</xref>, <xref rid="b0070" ref-type="bibr">Bovier, 2008b</xref><bold>)</bold>. No fatality was observed throughout the study. Four severe adverse effects viz. sepsis, arthralgia, psoas abscess<bold>,</bold> and joint abscess, were experienced by one volunteer, all effects were viewed as unrelated to <bold>the</bold> vaccine in questio<bold>n,</bold> and the volunteer was fully recovered. <bold>The</bold> percentage of volunteers who compla<bold>in</bold> for at least one treatmen<bold>t-e</bold>mergent adverse events were, 8.5%, 6.3%, and 13.8% with Influvac<bold>&#174;</bold>, Invivac<bold>&#174;</bold> and Fluad<bold>&#174;</bold>, respectively. The most frequented treatment<bold>-e</bold>mergent adverse events were, injection sit<bold>e-r</bold>elated erythema with Influvac (none) Invivac<bold>&#174;</bold> (0.8%), Fluad<bold>&#174;</bold> (2.3%); and arthralgia with Influvac<bold>&#174;</bold> (1.6%), Invivac<bold>&#174;</bold> (0.8%), Fluad<bold>&#174;</bold> (0.8%). Fluad<bold>&#174;</bold> related reactions were lasted in 3&#160;days, while Influvac<bold>&#174;</bold> and Invivac<bold>&#174;</bold> showed the reactions for 1&#8211;2&#160;days (<xref rid="b0155" ref-type="bibr">Bruijn et al., 2006</xref>).</p><p id="p0200">In elderly patients, virosom<bold>e-b</bold>ased influenza vaccines like Invivac<bold>&#174;</bold>, are as effective as orthodox influenza vaccine like Influvac<bold>&#174;</bold> or to the adjuvanted vaccine e.g., Fluad<bold>&#174;</bold> in context of <bold>the</bold> immunostimulatory effect of the HA of the three viral strains contained in the vaccines. Ideally, vaccines must meet for immunogenicity criteria in geriatric patients prescribed by Committee for Medicinal Products for Human Use (CHMP), for all three strains. It was found that Invivac<bold>&#174;</bold> was well tolerated and safe in geriatric patients. The tolerability and safety of Invivac<bold>&#174;</bold> was comparable to the Influvac<bold>&#174;</bold> standard influenza vaccine. Individuals immunized with the Fluad<bold>&#174;</bold>, an adjuvanted influenza vaccine, exhibit considerably more local reactions per individual than individuals immunized with Invivac<bold>&#174;</bold> or Influvac<bold>&#174;</bold>. However, local reactions after immunization with Fluad<bold>&#174;</bold> persist longer as compared to Influvac<bold>&#174;</bold> and Invivac<bold>&#174;</bold>. Conclusively, Invivac<bold>&#174;</bold> exhibit a comparable immunogenicity to the adjuvanted as well as standard influenza vaccine to the geriatric subjects and exhibit a better tolerability in comparison wit<bold>h F</bold>luad<bold>&#174;</bold> an adjuvanted influenza vaccine <bold>(</bold><xref rid="b0260" ref-type="bibr">Herzog et al., 2009</xref>, <xref rid="b0065" ref-type="bibr">Bovier, 2008a</xref>, <xref rid="b0070" ref-type="bibr">Bovier, 2008b</xref>, <xref rid="b0155" ref-type="bibr">de Bruijn et al., 2006</xref><bold>)</bold>.</p></sec></sec><sec id="s0065"><label>8</label><title>Patents</title><p id="p0205">Several inventions related to virosomes are protected by IPR. Patents related to virosomes cover several aspects, like their application as a vaccine delivery vehicle or drug carrier system, production process, unit operations involved in the production of virosomes like freeze drying, combination with other adjuvants etc. Including the patents covering various technical and industrial aspects protecting the nex<bold>t-g</bold>eneration virosomal carriers and applications of virosomes not yet approved at <bold>the</bold> industry scale. Virosomal know-how was protected by a patent, given to <bold>Berna Biotech (Crucell)</bold>, apply for an IRIV in combination with an antigen. Fundamentally, this patent comprises of the three virosome-based products viz. <bold>Epaxal</bold>&#174;<bold>, Epaxal</bold>&#174; <bold>Junior and Inflexal&#174; V.</bold> As far as the number of patents of virosom<bold>e-b</bold>ased technology are concerned, Pevion Biotech AG and Mymetics B.V. are the main assignees <bold>(</bold><xref rid="b0145" ref-type="bibr">Cusi et al., 2003</xref><bold>)</bold>. Many patents related to virosomal technology are assigned to the companies such as Novartis, Switzerland, and GlaxoSmithKline (GSK), United Kingdom. Another method of production of virosomes was patented, which is fundamentally based on the method of solubilization of the virus envelope composed of <bold>a</bold> short-chain phospholipid, was established by Mymetics BV in partnership with the University of Groningen <bold>(</bold><xref rid="b0350" ref-type="bibr">Luise et al., 2011</xref><bold>)</bold>. An immunopotentiating reconstituted influenza virosome (IRIV) consists of cationic cholesterol inserted in the phospholipid membrane was found to be appropriate for the freeze drying and its reconstitutio<bold>n</bold> was assigned to Pevion Bitech Limited. This technique permits thermostable virosom<bold>e-b</bold>ased vaccines with prolonged shelf-life <bold>(</bold><xref rid="b0575" ref-type="bibr">Zurbriggen et al., 2013a</xref><bold>)</bold>. Conventionally, influenza vaccines were prepared in chicken eggs. Though, the process based on cell-lines could be rapid, more reproducible, and versatile in context of virus propagation and also permits and ease the propagation of various strains that cannot be efficiently cultured in egg yolks. Remarkably, virosomes produced from influenza virus propagated in avian cell lines exhibited an improved immunogenicity and better fusion activity as compared to virosomes reconstituted from influenza viruses manufactured by the conventional methods employing chicken eggs <bold>(</bold><xref rid="b0580" ref-type="bibr">Zurbriggen et al., 2013b</xref><bold>)</bold>. Exploring other sources for the influenza virus envelope proteins and accurately defined compositions of virosomes, patent application shows that completely synthetic virosome based on recombinant HA may be attractive in the future <bold>(</bold><xref rid="b0170" ref-type="bibr">Di Naro, 2012</xref><bold>)</bold>. Several patents related to disease are filed and granted. <bold>An alphavirus HIV vaccine for the mitigation and prevention of AIDS was developed with the help of a joint venture of the University of North Carolina and AlphaVax Inc (</bold><xref rid="b0415" ref-type="bibr">Olmstedet al., 2004</xref><bold>). Janssen Vaccines AG, developed a reconstituted influenza virosomes-based immunopotentiating Hepatitis A virus vaccine (</bold><xref rid="b0215" ref-type="bibr">Glick and Mischler 1996</xref><bold>). Another patent was granted to Pevion Biotech for the successful development of an immunopotentiating vaccine against HIV (</bold><xref rid="b0200" ref-type="bibr">Fleury et al., 2015</xref><bold>). The GSK Biologicals was assigned a patent for an influenza virosome, fundamentally, the invention was related to the composition and structure of a virosome having influenza virus or RSV antigen, along with a saponin, as an adjuvant (</bold><xref rid="b0125" ref-type="bibr">Coller et al., 2015</xref><bold>). Another patent was assigned to the SmithKline Beecham Corp for the preparation of immunogenic influenza virosomes having a variety of microvesicles (</bold><xref rid="b0005" ref-type="bibr">Almeida and Edwards, 1980</xref><bold>). Moreover, Janssen Vaccines AG successfully produced a hybrid, membranous vesicle containing at least one lipid and enveloped proteins of influenza and hepatitis B virus (</bold><xref rid="b0395" ref-type="bibr">Moser et al., 2011</xref><bold>). Porcine reproductive and respiratory syndrome virus vaccine was developed&#160;and its production technique was invented at Chongqing University (</bold><xref rid="b0190" ref-type="bibr">Fenglin et al., 2011</xref><bold>). A novel cationic virosome for the effective delivery of nucleic acids to the resting as well as multiplying human cells for the treatment of cancer was invented by&#160;Nika Health Products Ltd&#160;(</bold><xref rid="b0530" ref-type="bibr">Walti et al., 2001</xref><bold>).&#160;An HIV virosome with novel immunogenic compositions was fabricated eliciting good immunogenicity by Emory University in collaboration with the National Institutes of Health (NIH), U.S. (</bold><xref rid="b0130" ref-type="bibr">Compans et al., 2010</xref><bold>).&#160;University of North Carolina, AlphaVax Inc., and University of Cape Town were granted a patent for the development of HIV-1 virosome based vaccine, which offered a new technique for the selection of HIV-1 (clade) C isolates, for the treatment and prophylaxis purpose (</bold><xref rid="b0295" ref-type="bibr">Johnston et al., 2007</xref><bold>). A patent revealing a successful development of respiratory syncytial virosome was granted to the Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, China&#160;(</bold><xref rid="b0565" ref-type="bibr">Zheng et al., 2011</xref><bold>)</bold>. A summary of patents associated with virosome as vaccine carrier in certain disease are mentioned&#160;in <xref rid="t0015" ref-type="table">Table 3</xref>.<table-wrap position="float" id="t0015" orientation="portrait"><label>Table 3</label><caption><p>Summary of some useful patents filed for delivery <bold>of</bold> virus vaccines through virosomes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Vaccine</bold></th><th colspan="1" rowspan="1"><bold>Description</bold></th><th colspan="1" rowspan="1"><bold>Assignee</bold></th><th colspan="1" rowspan="1"><bold>Legal status</bold></th><th colspan="1" rowspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">HIV Alphavirus</td><td colspan="1" rowspan="1">A HIV vaccine for the mitigation and prevention of AIDS.</td><td colspan="1" rowspan="1">University of North Carolina and AlphaVax Inc.</td><td colspan="1" rowspan="1">Active</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0415" ref-type="bibr">Olmstedet al., 2004</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Hepatitis A virus<break/></td><td colspan="1" rowspan="1">It consists of immunopotentiating Hepatitis A virus reconstituted influenza virosomes.<break/></td><td colspan="1" rowspan="1">Janssen Vaccines AG</td><td colspan="1" rowspan="1">Expired</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0215" ref-type="bibr">Glick and Mischler 1996</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">Suitable for immunopotentiation and instigation of an immune response against a HIV.</td><td colspan="1" rowspan="1">Pevion Biotech Ltd,&#160;Institut National de la Sante et de la Recherche Medicale, and<break/>Mymetics Corp</td><td colspan="1" rowspan="1">Active</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0200" ref-type="bibr">Fleury et al., 2015</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">It relates to structure and composition of&#160;virosome having influenza virus or RSV antigen, along with a saponin, as an adjuvant.</td><td colspan="1" rowspan="1">GSK Biologicals</td><td colspan="1" rowspan="1">Active</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0125" ref-type="bibr">Coller et al., 2015</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Immunogenic&#160;virosomes having a variety of microvesicles.</td><td colspan="1" rowspan="1">SmithKline Beecham Corp</td><td colspan="1" rowspan="1">Expired</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0005" ref-type="bibr">Almeida and Edwards, 1980</xref><bold>)</bold><break/></td></tr><tr><td colspan="1" rowspan="1">Influenza and Hepatitis B</td><td colspan="1" rowspan="1">Membranous vesicle containing at least one lipid and envelopes proteins of influenza and hepatitis B virus.</td><td colspan="1" rowspan="1">Janssen Vaccines AG</td><td colspan="1" rowspan="1">Active</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0395" ref-type="bibr">Moser et al., 2011</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Porcine reproductive and respiratory syndrome virus</td><td colspan="1" rowspan="1">Discuss about porcine reproductive and respiratory syndrome virus vaccine and its production technique.<break/></td><td colspan="1" rowspan="1">Chongqing University</td><td colspan="1" rowspan="1">Pending</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0190" ref-type="bibr">Fenglin et al., 2011</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Cancer</td><td colspan="1" rowspan="1">Tells about cationic virosome&#160;for the effective delivery of nucleic acids to resting as well as multiplying human cells.</td><td colspan="1" rowspan="1">Nika Health Products Ltd</td><td colspan="1" rowspan="1">Expired</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0530" ref-type="bibr">Walti et al., 2001</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">Describes virosome fabrication and immunogenic compositions, and eliciting an immunogenicity.</td><td colspan="1" rowspan="1">Emory University and <bold>N</bold>ational Institutes <bold>of</bold> Health (NIH), U.S.</td><td colspan="1" rowspan="1">Abandoned</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0130" ref-type="bibr">Compans et al., 2010</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">HIV-1</td><td colspan="1" rowspan="1">It offers a method for the selection of HIV-1 (clade) C isolates, selected HIV-1 subtype C isolates, their genes for use in prophylactic and therapeutic vaccines.</td><td colspan="1" rowspan="1">University of North Carolina,<break/>AlphaVax Inc., and<break/>University of Cape Town<break/></td><td colspan="1" rowspan="1">Abandoned</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0295" ref-type="bibr">Johnston et al., 2007</xref><bold>)</bold></td></tr><tr><td colspan="1" rowspan="1">Respiratory syncytial<break/><break/>virosome</td><td colspan="1" rowspan="1">This research reveals a respiratory syncytial&#160;virosome&#160;vaccine, which mainly comprises a respiratory syncytial&#160;virosome.</td><td colspan="1" rowspan="1">Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, China</td><td colspan="1" rowspan="1">Active</td><td colspan="1" rowspan="1"><bold>(</bold><xref rid="b0565" ref-type="bibr">Zheng et al., 2011</xref><bold>)</bold></td></tr></tbody></table></table-wrap></p></sec><sec id="s0070"><label>9</label><title>Future prospects</title><p id="p0210">Virosomal carrier system has not yet been comprehensively explored. The present gene delivery carriers have been extensively studied, recently from various clinical trials promising developments for viral delivery systems have been reported. Over the last few years, it has been comprehended that the advancements of a versatile gene delivery carrier are possibly to be misleading. Diseases that are treatable by the use of gene therapy are quite different and hence need personalized approaches of treatments. The management of some illnesses need an ample but transient protein expression, while other illnesses may only be cured by a regulated expression, generally, stoppage of expression of a particular gene for longer duration. In certain conditions, multiple or single genes must be presented into the nucleus of the target cell, whereas in other conditions cytoplasmic delivery of siRNA is enough. Furthermore, the type of the diseased cells like <bold>the</bold> mitotic and endocytic environment and the locale of the cells in the body play an important role to treat the disease. These different characteristics appeal for the development of delivery devices of nucleic that are customized for a specific purpose. Hence, it is of paramount significance tha<bold>t v</bold>arious types of delivery carriers become available prospectively, viral, or non-viral origin or hybrids of these. <bold>C</bold>omplications associated with DNA-virosomal carriers can be resolved, the virosomal drug carrier platform embodies the technology platform that can be effortlessly attuned to fulfill the need for the treatment of a particular disease and hence a significant involvement in the available resource of nucleic acid and monoclonal antibodies delivery in the future. <bold>Vaccination is the one of the most effective way for the treatment and prevention of infectious disease. Recently, a number of nanovaccines based virosomal formulations have been marketed against prevalent and life-threatening infections. To date severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are effective, but long-term protection is vulnerable to the occurrence of new virus variant. Currently, tremendous efforts were made to synthesize a virosome-based vaccine delivery system against a novel SARS-CoV-2 virus. Still, some untiring efforts are required to successfully prepare a robust safe, effective and reproducible virosome-based SARS-CoV-2 vaccine in clinical situation.</bold> Virosomes embody as novel drug carrier system for the delivery of various biologically active molecules but some aspects of virosomal drug delivery system such as IVIVC, stability, tolerability, optimization, scale-up are still topics to be discussed in detail.</p></sec><sec id="s0075"><label>10</label><title>Conclusion</title><p id="p0215">Conclusively, virosome embodies reconstituted virus envelope, excluding the nucleic acid of the native virus. As compared to the liposome, virosome possesses functionally active virus phospholipid membranous structure along with associated spike proteins and peptides intercalated in the envelop<bold>e</bold>. The clinically established features of virosome as antigen carrier as well as adjuvant have endorsed the progress and advancement in virosome-based vaccines having varied and new antigens. Although, possessing <bold>a</bold> simple structure, and easy fabrication methods, the activity of the product is dependent on the antigen and the costs associated with production, might prevent the broader applications of virosome for cost effective common preventative immunization products such as tetanus, diphtheria, hepatitis B, etc. Hence, due to increasing attention on alum-free antigenic immunization products virosomes are gaining significant consideration.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0225">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><mixed-citation publication-type="other" id="h0005">Almeida, J.D.; Edwards, D.C.,1980. Biological preparations. US Patent, US4196191A.</mixed-citation></ref><ref id="b0010"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Amacker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Engler</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kammer</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vadrucci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oberholzer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R.</given-names></name></person-group><article-title>Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells</article-title><source>Int. Immunol.</source><volume>17</volume><issue>6</issue><year>2005</year><fpage>695</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh249</pub-id><pub-id pub-id-type="pmid">15843436</pub-id></element-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Ambrosch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wiedermann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jonas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Althaus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>C.</given-names></name></person-group><article-title>Immunogenicity and protectivity of a new liposomal hepatitis A vaccine</article-title><source>Vaccine</source><volume>15</volume><issue>11</issue><year>1997</year><fpage>1209</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(97)00015-7</pub-id><pub-id pub-id-type="pmid">9286045</pub-id></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Angel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chaperot</surname><given-names>L.</given-names></name><name name-style="western"><surname>Molens</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Mezin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grichine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plumas</surname><given-names>J.</given-names></name></person-group><article-title>Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells</article-title><source>Vaccine</source><volume>25</volume><issue>19</issue><year>2007</year><fpage>3913</fpage><lpage>3921</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.101</pub-id><pub-id pub-id-type="pmid">17336432</pub-id></element-citation></ref><ref id="b0025"><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Arkema</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name></person-group><article-title>Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes</article-title><source>Vaccine</source><volume>18</volume><issue>14</issue><year>2000</year><fpage>1327</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(99)00404-1</pub-id><pub-id pub-id-type="pmid">10618529</pub-id></element-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Babar</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Kazi</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>A.</given-names></name></person-group><article-title>Virosomes hybrid drug delivery systems</article-title><source>J. Antivir. Antiretrovir.</source><volume>5</volume><year>2013</year><fpage>166</fpage><lpage>172</lpage></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Bagai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>D.P.</given-names></name></person-group><article-title>Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells</article-title><source>BBA</source><volume>1152</volume><issue>1</issue><year>1993</year><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(93)90226-p</pub-id><pub-id pub-id-type="pmid">8399293</pub-id></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Baghban</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mahmoodi</surname><given-names>S.</given-names></name></person-group><article-title>WITHDRAWN: nucleic acid-based vaccines platform against Covid-19 pandemic</article-title><source>Curr. Mol. Med.</source><year>2022</year><pub-id pub-id-type="doi">10.2174/1566524022666220106160403</pub-id><pub-id pub-id-type="pmid">34994327</pub-id></element-citation></ref><ref id="b0045"><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R.M.</given-names></name></person-group><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><volume>392</volume><issue>6673</issue><year>1998</year><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></element-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Baumgarth</surname><given-names>N.</given-names></name></person-group><article-title>A two-phase model of B-cell activation</article-title><source>Immunol. Rev.</source><volume>176</volume><year>2000</year><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065x.2000.00606.x</pub-id><pub-id pub-id-type="pmid">11043776</pub-id></element-citation></ref><ref id="b0055"><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mazumder</surname><given-names>M.</given-names></name></person-group><article-title>Virosomes: A novel strategy for drug delivery and targeting</article-title><source>BioPharm Int.</source><volume>2011</volume><issue>1</issue><year>2011</year></element-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Blissard</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Wenz</surname><given-names>J.R.</given-names></name></person-group><article-title>Baculovirus gp64 envelope glycoprotein is sufficient to mediate pH-dependent membrane fusion</article-title><source>J. Virol.</source><volume>66</volume><issue>11</issue><year>1992</year><fpage>6829</fpage><lpage>6835</lpage><pub-id pub-id-type="doi">10.1128/JVI.66.11.6829-6835.1992</pub-id><pub-id pub-id-type="pmid">1404622</pub-id><pub-id pub-id-type="pmcid">PMC240187</pub-id></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Bovier</surname><given-names>P.A.</given-names></name></person-group><article-title>Epaxal: a virosomal vaccine to prevent hepatitis A infection</article-title><source>Expert Rev. Vaccines</source><volume>7</volume><issue>8</issue><year>2008</year><fpage>1141</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.8.1141</pub-id><pub-id pub-id-type="pmid">18844588</pub-id></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Bovier</surname><given-names>P.A.</given-names></name></person-group><article-title>Recent advances with a virosomal hepatitis A vaccine</article-title><source>Expert Opin. Biol. Ther.</source><volume>8</volume><issue>8</issue><year>2008</year><fpage>1177</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1517/14712598.8.8.1177</pub-id><pub-id pub-id-type="pmid">18613769</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Bron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes)</article-title><source>Biochemistry</source><volume>33</volume><issue>31</issue><year>1994</year><fpage>9110</fpage><lpage>9117</lpage><pub-id pub-id-type="doi">10.1021/bi00197a013</pub-id><pub-id pub-id-type="pmid">8049214</pub-id></element-citation></ref><ref id="b0080"><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Bundy</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Franciszkowicz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>J.R.</given-names></name></person-group><article-title>Escherichia coli-based cell-free synthesis of virus-like particles</article-title><source>Biotechnol. Bioeng.</source><volume>100</volume><issue>1</issue><year>2008</year><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/bit.21716</pub-id><pub-id pub-id-type="pmid">18023052</pub-id></element-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Bungener</surname><given-names>L.</given-names></name><name name-style="western"><surname>Serre</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bijl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leserman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Machy</surname><given-names>P.</given-names></name></person-group><article-title>Virosome-mediated delivery of protein antigens to dendritic cells</article-title><source>Vaccine</source><volume>20</volume><issue>17&#8211;18</issue><year>2002</year><fpage>2287</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(02)00103-2</pub-id><pub-id pub-id-type="pmid">12009284</pub-id></element-citation></ref><ref id="b0090"><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Bungener</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Mare</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Vries-Idema</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name></person-group><article-title>Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity</article-title><source>Vaccine</source><volume>23</volume><issue>10</issue><year>2005</year><fpage>1232</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.002</pub-id><pub-id pub-id-type="pmid">15652665</pub-id></element-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Bungener</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Mare</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Vries-Idema</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sehr</surname><given-names>P.</given-names></name><name name-style="western"><surname>van der Zee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name></person-group><article-title>A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease</article-title><source>Antivir. Ther.</source><volume>11</volume><issue>6</issue><year>2006</year><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">17310816</pub-id></element-citation></ref><ref id="b0100"><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Cambi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>C.G.</given-names></name></person-group><article-title>Dual function of C-type lectin-like receptors in the immune system</article-title><source>Curr. Opin. Cell Biol.</source><volume>15</volume><issue>5</issue><year>2003</year><fpage>539</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2003.08.004</pub-id><pub-id pub-id-type="pmid">14519388</pub-id></element-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Canal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanchis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vicent</surname><given-names>M.J.</given-names></name></person-group><article-title>Polymer&#8211;drug conjugates as nano-sized medicines</article-title><source>Curr. Opin. Biotechnol.</source><volume>22</volume><issue>6</issue><year>2011</year><fpage>894</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2011.06.003</pub-id><pub-id pub-id-type="pmid">21724381</pub-id></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Carmona-Ribeiro</surname><given-names>A.M.</given-names></name></person-group><article-title>Biomimetic nanoparticles: preparation, characterization and biomedical applications</article-title><source>Int. J. Nanomed.</source><volume>5</volume><year>2010</year><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.2147/ijn.s9035</pub-id><pub-id pub-id-type="pmcid">PMC2865020</pub-id><pub-id pub-id-type="pmid">20463941</pub-id></element-citation></ref><ref id="b0115"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Champion</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Kickhoefer</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moniz</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Freed</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Vaccari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raval-Fernandes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rome</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>K.A.</given-names></name></person-group><article-title>A vault nanoparticle vaccine induces protective mucosal immunity</article-title><source>PLoS One</source><volume>4</volume><issue>4</issue><year>2009</year><fpage>e5409</fpage><pub-id pub-id-type="pmid">19404403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0005409</pub-id><pub-id pub-id-type="pmcid">PMC2671841</pub-id></element-citation></ref><ref id="b0120"><mixed-citation publication-type="other" id="h0120">ClinicalTrials.gov, National Library of Medicine, National Institutes of Health, Bathesda, Maryland, USA.URL:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=%26term=virosomes%26cntry=%26state=%26city=%26dist=" id="ir005">https://clinicaltrials.gov/ct2/results?cond=&amp;term=virosomes&amp;cntry=&amp;state=&amp;city=&amp;dist=</ext-link> (Retrieved on 10-12-2022).</mixed-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Coller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Henderickx</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.M.J.</given-names></name></person-group><article-title>Vaccine compositions comprising virosomes and a saponin adjuvant</article-title><source>Australian Patent</source><volume>AU2005249212B2</volume><year>2015</year></element-citation></ref><ref id="b0130"><mixed-citation publication-type="other" id="h0130">Compans, R.W.; Yang, C.; Yao, Q.; Kang, S.M.,2010. Virosomes, methods of preparation, and immunogenic compositions. US Patent, 2010, US20100047277A1.</mixed-citation></ref><ref id="b0145"><mixed-citation publication-type="other" id="h0145">Cusi, M.; Gluck, R.; Walti, E.,2003. Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them, US Patent, US20030113347A1.</mixed-citation></ref><ref id="b9010"><element-citation publication-type="journal" id="h9010"><person-group person-group-type="author"><name name-style="western"><surname>Cusi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Del Vecchio</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Terrosi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Savellini</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Di Genova</surname><given-names>G.</given-names></name><name name-style="western"><surname>La Placa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fallarino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cardone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Francini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Correale</surname><given-names>P.</given-names></name></person-group><article-title>Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine</article-title><source>Journal of immunology (Baltimore, Md.)</source><volume>174</volume><issue>11</issue><year>2005</year><fpage>7210</fpage><lpage>7216</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.11.7210</pub-id><pub-id pub-id-type="pmid">15905566</pub-id></element-citation></ref><ref id="b0135"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Cusi</surname><given-names>M.G.</given-names></name></person-group><article-title>Applications of influenza virosomes as a delivery system</article-title><source>Hum. Vaccin.</source><volume>2</volume><issue>1</issue><year>2006</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4161/hv.2.1.2494</pub-id><pub-id pub-id-type="pmid">17012895</pub-id></element-citation></ref><ref id="b0150"><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>de Bruijn</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Nauta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gerez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Palache</surname><given-names>A.M.</given-names></name></person-group><article-title>Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers</article-title><source>Virus Res.</source><volume>103</volume><issue>1&#8211;2</issue><year>2004</year><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2004.02.026</pub-id><pub-id pub-id-type="pmid">15163502</pub-id></element-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>de Bruijn</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Nauta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gerez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Palache</surname><given-names>A.M.</given-names></name></person-group><article-title>The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects</article-title><source>Vaccine</source><volume>24</volume><issue>44&#8211;46</issue><year>2006</year><fpage>6629</fpage><lpage>6631</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.035</pub-id><pub-id pub-id-type="pmid">16901593</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>de Bruijn</surname><given-names>I.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gerez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nauta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giezeman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Palache</surname><given-names>B.</given-names></name></person-group><article-title>Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly</article-title><source>Vaccine</source><volume>26</volume><issue>1</issue><year>2007</year><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.10.051</pub-id><pub-id pub-id-type="pmid">18063446</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Deniger</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Kolokoltsov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>R.A.</given-names></name></person-group><article-title>Targeting and penetration of virus receptor bearing cells by nanoparticles coated with envelope proteins of Moloney murine leukemia virus</article-title><source>Nano Lett.</source><volume>6</volume><issue>11</issue><year>2006</year><fpage>2414</fpage><lpage>2421</lpage><pub-id pub-id-type="doi">10.1021/nl061180z</pub-id><pub-id pub-id-type="pmid">17090066</pub-id></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Di Naro</surname><given-names>M.</given-names></name></person-group><article-title>Generation of virosome particles</article-title><source>European Patent</source><volume>EP2622082A1</volume><year>2012</year></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Dijkstra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Haan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.L.</given-names></name></person-group><article-title>Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes)</article-title><source>J. Immunol. (Baltimore, Md. : 1950)</source><volume>157</volume><issue>3</issue><year>1996</year><fpage>1028</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">8757606</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Durrer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hoenke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vorherr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>J.</given-names></name></person-group><article-title>H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region</article-title><source>J. Biol. Chem.</source><volume>271</volume><issue>23</issue><year>1996</year><fpage>13417</fpage><lpage>13421</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.23.13417</pub-id><pub-id pub-id-type="pmid">8662770</pub-id></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Felnerova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Viret</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name></person-group><article-title>Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs</article-title><source>Curr. Opin. Biotechnol.</source><volume>15</volume><issue>6</issue><year>2004</year><fpage>518</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2004.10.005</pub-id><pub-id pub-id-type="pmid">15560978</pub-id></element-citation></ref><ref id="b0190"><mixed-citation publication-type="other" id="h0190">Fenglin, L.; Zheng, C.; Li, Y.; Feifei T., 2011. Porcine reproductive and respiratory syndrome Virosome vaccine and preparation method thereof. Chinese Patent, CN102107003A.</mixed-citation></ref><ref id="b0195"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Fifis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mottram</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogdanoska</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name></person-group><article-title>Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice</article-title><source>Vaccine</source><volume>23</volume><issue>2</issue><year>2004</year><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.05.022</pub-id><pub-id pub-id-type="pmid">15531045</pub-id></element-citation></ref><ref id="b0200"><mixed-citation publication-type="other" id="h0200">Fleury, S.; Bomsel, M.; Zurbriggen, R.,2015. Virosome-like vesicles comprising gp41-derived antigens. US Patent , US9216156B2.</mixed-citation></ref><ref id="b0205"><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>Geerligs</surname><given-names>H.</given-names></name><name name-style="western"><surname>Quanz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suurland</surname><given-names>B.</given-names></name><name name-style="western"><surname>Spijkers</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Rodenberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davelaar</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Jongsma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens</article-title><source>Vaccine</source><volume>26</volume><issue>44</issue><year>2008</year><fpage>5595</fpage><lpage>5600</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.080</pub-id><pub-id pub-id-type="pmid">18706949</pub-id></element-citation></ref><ref id="b0215"><mixed-citation publication-type="other" id="h0215">Glick, R.; Mischler, R.,1996. Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine. US Patent, US5565203A.</mixed-citation></ref><ref id="b0220"><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name><name name-style="western"><surname>W&#228;lti</surname><given-names>E.</given-names></name></person-group><article-title>Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV)</article-title><source>Dev. Biol.</source><volume>103</volume><year>2000</year><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">11214236</pub-id></element-citation></ref><ref id="b0225"><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mischler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Que</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Immunogenicity of new virosome influenza vaccine in elderly people</article-title><source>Lancet (London, England)</source><volume>344</volume><issue>8916</issue><year>1994</year><fpage>160</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(94)92758-8</pub-id><pub-id pub-id-type="pmid">7912766</pub-id></element-citation></ref><ref id="b0230"><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>J.F.</given-names></name></person-group><article-title>A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery</article-title><source>Adv. Drug Deliv. Rev.</source><volume>54</volume><issue>6</issue><year>2002</year><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/s0169-409x(02)00072-8</pub-id><pub-id pub-id-type="pmid">12363434</pub-id></element-citation></ref><ref id="b0235"><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>G&#252;nther-Ausborn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bartoldus</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stegmann</surname><given-names>T.</given-names></name></person-group><article-title>Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity</article-title><source>J. Virol.</source><volume>74</volume><issue>6</issue><year>2000</year><fpage>2714</fpage><lpage>2720</lpage><pub-id pub-id-type="doi">10.1128/jvi.74.6.2714-2720.2000</pub-id><pub-id pub-id-type="pmid">10684287</pub-id><pub-id pub-id-type="pmcid">PMC111761</pub-id></element-citation></ref><ref id="b0240"><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bushweller</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Cafiso</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Tamm</surname><given-names>L.K.</given-names></name></person-group><article-title>Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin</article-title><source>Nat. Struct. Biol.</source><volume>8</volume><issue>8</issue><year>2001</year><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1038/90434</pub-id><pub-id pub-id-type="pmid">11473264</pub-id></element-citation></ref><ref id="b0245"><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Hatz</surname><given-names>C.</given-names></name><name name-style="western"><surname>van der Ploeg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Fr&#246;sner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>C.</given-names></name></person-group><article-title>Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years</article-title><source>Clinical and vaccine immunology : CVI</source><volume>18</volume><issue>5</issue><year>2011</year><fpage>885</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1128/CVI.00358-10</pub-id><pub-id pub-id-type="pmid">21411599</pub-id><pub-id pub-id-type="pmcid">PMC3122528</pub-id></element-citation></ref><ref id="b0250"><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kunisawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kondoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imazu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamaoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mayumi</surname><given-names>T.</given-names></name></person-group><article-title>A novel vaccine delivery system using immunopotentiating fusogenic liposomes</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>261</volume><issue>3</issue><year>1999</year><fpage>824</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.1044</pub-id><pub-id pub-id-type="pmid">10441509</pub-id></element-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name name-style="western"><surname>Gheibi Hayat</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Darroudi</surname><given-names>M.</given-names></name></person-group><article-title>Nanovaccine: A novel approach in immunization</article-title><source>J. Cell. Physiol.</source><volume>234</volume><issue>8</issue><year>2019</year><fpage>12530</fpage><lpage>12536</lpage><pub-id pub-id-type="doi">10.1002/jcp.28120</pub-id><pub-id pub-id-type="pmid">30633361</pub-id></element-citation></ref><ref id="b0255"><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Wolfsberg</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>White</surname><given-names>J.M.</given-names></name></person-group><article-title>Virus-cell and cell-cell fusion</article-title><source>Annu. Rev. Cell Dev. Biol.</source><volume>12</volume><year>1996</year><fpage>627</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.12.1.627</pub-id><pub-id pub-id-type="pmid">8970739</pub-id></element-citation></ref><ref id="b0260"><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Herzog</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>K&#252;nzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>K&#252;rsteiner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mischler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name></person-group><article-title>Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine</article-title><source>Vaccine</source><volume>27</volume><issue>33</issue><year>2009</year><fpage>4381</fpage><lpage>4387</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.029</pub-id><pub-id pub-id-type="pmid">19450630</pub-id></element-citation></ref><ref id="b0265"><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bungener</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Influenza virosomes in vaccine development</article-title><source>Methods Enzymol.</source><volume>373</volume><year>2003</year><fpage>74</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(03)73005-5</pub-id><pub-id pub-id-type="pmid">14714397</pub-id></element-citation></ref><ref id="b0275"><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bungener</surname><given-names>L.</given-names></name><name name-style="western"><surname>ter Veer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Holtrop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Palache</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity</article-title><source>Vaccine</source><volume>21</volume><issue>9&#8211;10</issue><year>2003</year><fpage>925</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(02)00542-x</pub-id><pub-id pub-id-type="pmid">12547604</pub-id></element-citation></ref><ref id="b0270"><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bungener</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stegmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Medema</surname><given-names>J.</given-names></name><name name-style="western"><surname>Palache</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>The virosome concept for influenza vaccines</article-title><source>Vaccine</source><volume>23</volume><issue>Suppl 1</issue><year>2005</year><fpage>S26</fpage><lpage>S38</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.04.026</pub-id><pub-id pub-id-type="pmid">16026906</pub-id></element-citation></ref><ref id="b0280"><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holtrop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Cellular delivery of siRNA mediated by fusion-active virosomes</article-title><source>J. Liposome Res.</source><volume>17</volume><issue>1</issue><year>2007</year><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1080/08982100601186516</pub-id><pub-id pub-id-type="pmid">17454402</pub-id></element-citation></ref><ref id="b0285"><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Hug</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sleight</surname><given-names>R.G.</given-names></name></person-group><article-title>Fusogenic virosomes prepared by partitioning of vesicular stomatitis virus G protein into preformed vesicles</article-title><source>J. Biol. Chem.</source><volume>269</volume><issue>6</issue><year>1994</year><fpage>4050</fpage><lpage>4056</lpage><pub-id pub-id-type="pmid">8307962</pub-id></element-citation></ref><ref id="b0290"><element-citation publication-type="book" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>K.K.</given-names></name></person-group><part-title>The Handbook of Nanomedicine</part-title><year>2008</year><publisher-name>Humana Press</publisher-name><publisher-loc>Springer, London, UK</publisher-loc></element-citation></ref><ref id="b0295"><mixed-citation publication-type="other" id="h0295">Johnston, R.; Karim, S.; Morris, L.; Swanstrom, R.; Williamson, C.,2007. Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof. US Patent, US20070172930A1.</mixed-citation></ref><ref id="b0300"><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Kaneda</surname><given-names>Y.</given-names></name></person-group><article-title>Virosomes: evolution of the liposome as a targeted drug delivery system</article-title><source>Adv. Drug Deliv. Rev.</source><volume>43</volume><issue>2&#8211;3</issue><year>2000</year><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/s0169-409x(00)00069-7</pub-id><pub-id pub-id-type="pmid">10967226</pub-id></element-citation></ref><ref id="b0305"><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Karimi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Salicioni</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kambayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>C.L.</given-names></name></person-group><article-title>Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay</article-title><source>PLoS One</source><volume>9</volume><issue>2</issue><year>2014</year><fpage>e89357</fpage><pub-id pub-id-type="pmid">24586714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0089357</pub-id><pub-id pub-id-type="pmcid">PMC3929704</pub-id></element-citation></ref><ref id="b0310"><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mendel</surname><given-names>D.B.</given-names></name></person-group><article-title>Neuraminidase inhibitors as anti-influenza virus agents</article-title><source>Antivir. Chem. Chemother.</source><volume>10</volume><issue>4</issue><year>1999</year><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1177/095632029901000401</pub-id><pub-id pub-id-type="pmid">10480735</pub-id></element-citation></ref><ref id="b0315"><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamachari</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geary</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A.K.</given-names></name></person-group><article-title>Nanoparticle delivery systems in cancer vaccines</article-title><source>Pharm. Res.</source><volume>28</volume><issue>2</issue><year>2011</year><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s11095-010-0241-4</pub-id><pub-id pub-id-type="pmid">20721603</pub-id><pub-id pub-id-type="pmcid">PMC3559243</pub-id></element-citation></ref><ref id="b0320"><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Kushnir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Streatfield</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V.</given-names></name></person-group><article-title>Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development</article-title><source>Vaccine</source><volume>31</volume><issue>1</issue><year>2012</year><fpage>58</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.083</pub-id><pub-id pub-id-type="pmid">23142589</pub-id><pub-id pub-id-type="pmcid">PMC7115575</pub-id></element-citation></ref><ref id="b0325"><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>Y.N.</given-names></name></person-group><article-title>BNT162b2 mRNA COVID-19 Vaccine: First Approval</article-title><source>Drugs</source><volume>81</volume><issue>4</issue><year>2021</year><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01480-7</pub-id><pub-id pub-id-type="pmid">33683637</pub-id><pub-id pub-id-type="pmcid">PMC7938284</pub-id></element-citation></ref><ref id="b0330"><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>van Engelenburg</surname><given-names>F.</given-names></name><name name-style="western"><surname>van den Dobbelsteen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopalco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bomsel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chalifour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fleury</surname><given-names>S.</given-names></name></person-group><article-title>Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes</article-title><source>PLoS One</source><volume>8</volume><issue>2</issue><year>2013</year><fpage>e55438</fpage><pub-id pub-id-type="pmid">23437055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0055438</pub-id><pub-id pub-id-type="pmcid">PMC3577797</pub-id></element-citation></ref><ref id="b0335"><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kromann</surname><given-names>I.</given-names></name><name name-style="western"><surname>Giemza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>E.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thierry-Carstensen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Novicki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group><article-title>Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin</article-title><source>PLoS One</source><volume>4</volume><issue>9</issue><year>2009</year><fpage>e6999</fpage><pub-id pub-id-type="pmid">19756141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0006999</pub-id><pub-id pub-id-type="pmcid">PMC2737308</pub-id></element-citation></ref><ref id="b0340"><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>DNA vaccines: an historical perspective and view to the future</article-title><source>Immunol. Rev.</source><volume>239</volume><issue>1</issue><year>2011</year><fpage>62</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00980.x</pub-id><pub-id pub-id-type="pmid">21198665</pub-id></element-citation></ref><ref id="b0345"><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>R.</given-names></name></person-group><article-title>Virus-like particles-universal molecular toolboxes</article-title><source>Curr. Opin. Biotechnol.</source><volume>18</volume><issue>6</issue><year>2007</year><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.013</pub-id><pub-id pub-id-type="pmid">18083549</pub-id><pub-id pub-id-type="pmcid">PMC7126091</pub-id></element-citation></ref><ref id="b0350"><mixed-citation publication-type="other" id="h0350">Luise, A.; Huckriede, W.; de Jonge, J.M.; Johannes, A.; Stegmann, H.; Schoen, P.J.; Wilschut, J.C.,2011. Virosome-like-particles. US Patent, US7901920B2.</mixed-citation></ref><ref id="b0355"><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janeway</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Innate immunity: the virtues of a nonclonal system of recognition</article-title><source>Cell</source><volume>91</volume><issue>3</issue><year>1997</year><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)80412-2</pub-id><pub-id pub-id-type="pmid">9363937</pub-id></element-citation></ref><ref id="b0360"><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name name-style="western"><surname>Mikule</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reissaar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Villers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takoupo Penka</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Temerev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rozanova</surname><given-names>L.</given-names></name></person-group><article-title>The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia's Vaccine Rollout Slower than That of Other Nations?</article-title><source>Epidemiologia (Basel, Switzerland)</source><volume>2</volume><issue>3</issue><year>2021</year><fpage>360</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.3390/epidemiologia2030027</pub-id><pub-id pub-id-type="pmid">36417231</pub-id><pub-id pub-id-type="pmcid">PMC9620906</pub-id></element-citation></ref><ref id="b0365"><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name name-style="western"><surname>Mineev</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lyukmanova</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Krabben</surname><given-names>L.</given-names></name><name name-style="western"><surname>Serebryakova</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Shulepko</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Arseniev</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kordyukova</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Veit</surname><given-names>M.</given-names></name></person-group><article-title>Structural investigation of influenza virus hemagglutinin membrane-anchoring peptide</article-title><source>Protein Eng. Des. Selection : PEDS</source><volume>26</volume><issue>9</issue><year>2013</year><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1093/protein/gzt034</pub-id><pub-id pub-id-type="pmid">23873663</pub-id></element-citation></ref><ref id="b0370"><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name name-style="western"><surname>Mischler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>I.C.</given-names></name></person-group><article-title>Inflexal V a trivalent virosome subunit influenza vaccine: production</article-title><source>Vaccine</source><volume>20</volume><issue>Suppl 5</issue><year>2002</year><fpage>B17</fpage><lpage>B23</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(02)00512-1</pub-id><pub-id pub-id-type="pmid">12477413</pub-id></element-citation></ref><ref id="b0375"><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name name-style="western"><surname>Mizuguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mayumi</surname><given-names>T.</given-names></name></person-group><article-title>Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy</article-title><source>Br. J. Cancer</source><volume>73</volume><issue>4</issue><year>1996</year><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/bjc.1996.83</pub-id><pub-id pub-id-type="pmid">8595161</pub-id><pub-id pub-id-type="pmcid">PMC2074455</pub-id></element-citation></ref><ref id="b0380"><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name name-style="western"><surname>Mizuguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kondoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mayumi</surname><given-names>T.</given-names></name></person-group><article-title>Fusion of sendai virus with liposome depends on only F protein, but not HN protein</article-title><source>Virus Res.</source><volume>59</volume><issue>2</issue><year>1999</year><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/s0168-1702(98)00137-3</pub-id><pub-id pub-id-type="pmid">10082390</pub-id></element-citation></ref><ref id="b0385"><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name name-style="western"><surname>Mohanraj</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Prestidge</surname><given-names>C.A.</given-names></name></person-group><article-title>Silica nanoparticle coated liposomes: a new type of hybrid nanocapsule for proteins</article-title><source>Int. J. Pharm.</source><volume>392</volume><issue>1&#8211;2</issue><year>2010</year><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.03.061</pub-id><pub-id pub-id-type="pmid">20363300</pub-id></element-citation></ref><ref id="b0390"><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Viret</surname><given-names>J.F.</given-names></name></person-group><article-title>Virosomal adjuvanted antigen delivery systems</article-title><source>Expert Rev. Vaccines</source><volume>2</volume><issue>2</issue><year>2003</year><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1586/14760584.2.2.189</pub-id><pub-id pub-id-type="pmid">12899570</pub-id></element-citation></ref><ref id="b0395"><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Assero</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fichera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lempereur</surname><given-names>L.</given-names></name><name name-style="western"><surname>Felnerova</surname><given-names>D.</given-names></name></person-group><article-title>Virosome particles comprising antigens from influenza virus and hepatitis B virus</article-title><source>European Patent</source><volume>EP1802746B1</volume><year>2011</year></element-citation></ref><ref id="b0400"><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name name-style="western"><surname>Mutsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Linder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spyr</surname><given-names>C.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>R.</given-names></name></person-group><article-title>Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland</article-title><source>N. Engl. J. Med.</source><volume>350</volume><issue>9</issue><year>2004</year><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id><pub-id pub-id-type="pmid">14985487</pub-id></element-citation></ref><ref id="b0405"><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name name-style="western"><surname>Nakanishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kunisawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsutsumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yashiro-Ohtani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamaoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mayumi</surname><given-names>T.</given-names></name></person-group><article-title>Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway</article-title><source>Eur. J. Immunol.</source><volume>30</volume><issue>6</issue><year>2000</year><fpage>1740</fpage><lpage>1747</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-4141(200006)30:6&amp;#x0003c;1740::AID-IMMU1740&amp;#x0003e;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">10898512</pub-id></element-citation></ref><ref id="b0410"><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name name-style="western"><surname>Nunes-Correia</surname><given-names>I.</given-names></name><name name-style="western"><surname>Eul&#225;lio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nir</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#252;zg&#252;nes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ramalho-Santos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedroso de Lima</surname><given-names>M.C.</given-names></name></person-group><article-title>Fluorescent probes for monitoring virus fusion kinetics: comparative evaluation of reliability</article-title><source>BBA</source><volume>1561</volume><issue>1</issue><year>2002</year><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/s0005-2736(01)00457-6</pub-id><pub-id pub-id-type="pmid">11988181</pub-id></element-citation></ref><ref id="b0415"><mixed-citation publication-type="other" id="h0415">Olmsted, R.; Keith, P.; Dryga, S.; Caley, I.; Maughan, M.; Johnston, R.; Davis, N.; Swanstrom, R.,2004. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines. US Patent, US6783,939B2.</mixed-citation></ref><ref id="b0420"><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name name-style="western"><surname>Ozkan</surname><given-names>M.</given-names></name></person-group><article-title>Quantum dots and other nanoparticles: what can they offer to drug discovery?</article-title><source>Drug Discov. Today</source><volume>9</volume><issue>24</issue><year>2004</year><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1016/S1359-6446(04)03291-X</pub-id><pub-id pub-id-type="pmid">15582795</pub-id></element-citation></ref><ref id="b0425"><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles</article-title><source>FEBS J.</source><volume>279</volume><issue>7</issue><year>2012</year><fpage>1198</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08512.x</pub-id><pub-id pub-id-type="pmid">22309233</pub-id></element-citation></ref><ref id="b0430"><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>K.G.</given-names></name></person-group><article-title>Influenza A virus: a model for viral antigen presentation to cytotoxic T lymphocytes</article-title><source>Semin. Virol.</source><volume>7</volume><year>1996</year><fpage>61</fpage><lpage>73</lpage></element-citation></ref><ref id="b0435"><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name name-style="western"><surname>Praetorius</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>T.K.</given-names></name></person-group><article-title>Engineered nanoparticles in cancer therapy</article-title><source>Recent Pat. Drug Deliv. Formul.</source><volume>1</volume><issue>1</issue><year>2007</year><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.2174/187221107779814104</pub-id><pub-id pub-id-type="pmid">19075873</pub-id></element-citation></ref><ref id="b0440"><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cody</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saucier-Sawyer</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Saltzman</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Edelson</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Birchall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hanlon</surname><given-names>D.J.</given-names></name></person-group><article-title>Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><volume>7</volume><issue>1</issue><year>2011</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2010.07.002</pub-id><pub-id pub-id-type="pmcid">PMC3073408</pub-id><pub-id pub-id-type="pmid">20692374</pub-id></element-citation></ref><ref id="b0445"><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name name-style="western"><surname>Sa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.W.</given-names></name></person-group><article-title>The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data</article-title><source>Vaccines</source><volume>10</volume><issue>2</issue><year>2022</year><fpage>320</fpage><pub-id pub-id-type="doi">10.3390/vaccines10020320</pub-id><pub-id pub-id-type="pmid">35214779</pub-id><pub-id pub-id-type="pmcid">PMC8879025</pub-id></element-citation></ref><ref id="b0450"><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name name-style="western"><surname>Saroja</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lakshmi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bhaskaran</surname><given-names>S.</given-names></name></person-group><article-title>Recent trends in vaccine delivery systems: a review</article-title><source>Int. J. Pharm. Investigation</source><volume>1</volume><issue>2</issue><year>2011</year><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.4103/2230-973X.82384</pub-id><pub-id pub-id-type="pmcid">PMC3465129</pub-id><pub-id pub-id-type="pmid">23071924</pub-id></element-citation></ref><ref id="b0455"><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name name-style="western"><surname>Schaller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korting</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Baur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Monod</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beinhauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hube</surname><given-names>B.</given-names></name></person-group><article-title>The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium</article-title><source>Infect Immun.</source><volume>71</volume><issue>6</issue><year>2003 Jun</year><fpage>3227</fpage><lpage>3234</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.6.3227-3234.2003</pub-id><pub-id pub-id-type="pmid">12761103</pub-id><pub-id pub-id-type="pmcid">PMC155757</pub-id></element-citation></ref><ref id="b0460"><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name name-style="western"><surname>Schoen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leserman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions</article-title><source>FEBS Lett.</source><volume>390</volume><issue>3</issue><year>1996</year><fpage>315</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(96)00682-5</pub-id><pub-id pub-id-type="pmid">8706885</pub-id></element-citation></ref><ref id="b0465"><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yasir</surname><given-names>M.</given-names></name></person-group><article-title>Virosomes: A novel carrier for drug delivery</article-title><source>Int. J. Pharm. Tech. Res.</source><volume>2</volume><year>2010</year><fpage>2327</fpage><lpage>2339</lpage></element-citation></ref><ref id="b0470"><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name></person-group><article-title>Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses</article-title><source>Cancer Biother. Radiopharm.</source><volume>20</volume><issue>4</issue><year>2005</year><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1089/cbr.2005.20.401</pub-id><pub-id pub-id-type="pmid">16114988</pub-id></element-citation></ref><ref id="b0475"><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sapsford</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ligler</surname><given-names>F.S.</given-names></name></person-group><article-title>Optimization of antibody-conjugated magnetic nanoparticles for target preconcentration and immunoassays</article-title><source>Anal. Biochem.</source><volume>410</volume><issue>1</issue><year>2011</year><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2010.11.005</pub-id><pub-id pub-id-type="pmid">21078282</pub-id><pub-id pub-id-type="pmcid">PMC3670747</pub-id></element-citation></ref><ref id="b0480"><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name name-style="western"><surname>Stegmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morselt</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Booy</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>van Breemen</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Scherphof</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name></person-group><article-title>Functional reconstitution of influenza virus envelopes</article-title><source>EMBO J.</source><volume>6</volume><issue>9</issue><year>1987</year><fpage>2651</fpage><lpage>2659</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1987.tb02556.x</pub-id><pub-id pub-id-type="pmid">3678202</pub-id><pub-id pub-id-type="pmcid">PMC553686</pub-id></element-citation></ref><ref id="b0485"><element-citation publication-type="book" id="h0485"><person-group person-group-type="author"><name name-style="western"><surname>Stevenson</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>P.C.</given-names></name></person-group><part-title>Cell-mediated immune responses to influenza virus</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Nicholson</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>A.J.</given-names></name></person-group><source>Textbook of influenza</source><year>1998</year><publisher-name>Blackwell Science</publisher-name><fpage>333</fpage><lpage>345</lpage></element-citation></ref><ref id="b0490"><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name name-style="western"><surname>Stockley</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Stonehouse</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Valeg&#229;rd</surname><given-names>K.</given-names></name></person-group><article-title>Molecular mechanism of RNA phage morphogenesis</article-title><source>Int. J. Biochem.</source><volume>26</volume><issue>10&#8211;11</issue><year>1994</year><fpage>1249</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/0020-711x(94)90094-9</pub-id><pub-id pub-id-type="pmid">7851629</pub-id></element-citation></ref><ref id="b0495"><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>407</volume><issue>1</issue><year>2011</year><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.02.122</pub-id><pub-id pub-id-type="pmid">21362402</pub-id></element-citation></ref><ref id="b0500"><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name name-style="western"><surname>Tamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>F.A.</given-names></name></person-group><article-title>Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses</article-title><source>J. Virol.</source><volume>68</volume><issue>6</issue><year>1994</year><fpage>3499</fpage><lpage>3504</lpage><pub-id pub-id-type="doi">10.1128/JVI.68.6.3499-3504.1994</pub-id><pub-id pub-id-type="pmid">8189489</pub-id><pub-id pub-id-type="pmcid">PMC236853</pub-id></element-citation></ref><ref id="b0505"><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name name-style="western"><surname>Tofoli</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Cereda</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Groppo</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Volpato</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Franz-Montan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ranali</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>de Paula</surname><given-names>E.</given-names></name></person-group><article-title>Efficacy of liposome-encapsulated mepivacaine for infiltrative anesthesia in volunteers</article-title><source>J. Liposome Res.</source><volume>21</volume><issue>1</issue><year>2011</year><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3109/08982104.2010.483596</pub-id><pub-id pub-id-type="pmid">20482446</pub-id></element-citation></ref><ref id="b0510"><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name name-style="western"><surname>Trombetta</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Cell biology of antigen processing in vitro and in vivo</article-title><source>Annu. Rev. Immunol.</source><volume>23</volume><year>2005</year><fpage>975</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104538</pub-id><pub-id pub-id-type="pmid">15771591</pub-id></element-citation></ref><ref id="b0515"><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name name-style="western"><surname>Tukhvatulin</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kovyrshina</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lubenets</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Grousova</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Erokhova</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Botikov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Izhaeva</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Popova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ozharovskaia</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Esmagambetov</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Favorskaya</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Zrelkin</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Voronina</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Shcherbinin</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Semikhin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Simakova</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Gintsburg</surname><given-names>A.L.</given-names></name></person-group><article-title>An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine &#8220;Sputnik Light&#8221; for prevention of coronavirus infection in healthy adults</article-title><source>The Lancet regional health. Europe</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">100241</object-id><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100241</pub-id><pub-id pub-id-type="pmcid">PMC8562788</pub-id><pub-id pub-id-type="pmid">34746910</pub-id></element-citation></ref><ref id="b0520"><mixed-citation publication-type="other" id="h0520">United States Department of Health and Human Services U.S. Food and Drug Administration, Silver Spring, Maryland, United States. 2022,URL: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines" id="ir015">https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines</ext-link>.</mixed-citation></ref><ref id="b0525"><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>D.P.</given-names></name></person-group><article-title>Histidylated lipid-modified Sendai viral envelopes mediate enhanced membrane fusion and potentiate targeted gene delivery</article-title><source>J. Biol. Chem.</source><volume>280</volume><issue>42</issue><year>2005</year><fpage>35399</fpage><lpage>35409</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506615200</pub-id><pub-id pub-id-type="pmid">16085643</pub-id></element-citation></ref><ref id="b0530"><mixed-citation publication-type="other" id="h0530">Walti, E.R.; Gluck, R.; Klein, P.,2001. Cationic virosomes as transfer system for genetic material. US Patent 2001, US6210708B1.</mixed-citation></ref><ref id="b0535"><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>P.</given-names></name></person-group><article-title>Virosome, a promising delivery vehicle for siRNA delivery and its novel preparation method</article-title><source>J. Drug Deliv. Sci. Tech</source><volume>74</volume><year>2022</year><object-id pub-id-type="publisher-id">103490</object-id><comment>ISSN 1773&#8211;2247.</comment></element-citation></ref><ref id="b0540"><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Paesold</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mischler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Semenza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>J.</given-names></name></person-group><article-title>Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane</article-title><source>J. Biol. Chem.</source><volume>269</volume><issue>28</issue><year>1994</year><fpage>18353</fpage><lpage>18358</lpage><pub-id pub-id-type="pmid">8034580</pub-id></element-citation></ref><ref id="b0545"><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide</article-title><source>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</source><volume>63</volume><issue>4</issue><year>2009</year><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2008.07.086</pub-id><pub-id pub-id-type="pmid">18823738</pub-id></element-citation></ref><ref id="b0550"><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name name-style="western"><surname>Widjaja</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ilyushina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs</article-title><source>Virology</source><volume>350</volume><issue>1</issue><year>2006</year><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.02.020</pub-id><pub-id pub-id-type="pmid">16545416</pub-id></element-citation></ref><ref id="b0555"><element-citation publication-type="journal" id="h0555"><person-group person-group-type="author"><name name-style="western"><surname>Wiedermann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wiltschke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jasinska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kundi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garner-Spitzer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Steger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pehamberger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Scheiner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zielinski</surname><given-names>C.C.</given-names></name></person-group><article-title>A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study</article-title><source>Breast Cancer Res. Treat.</source><volume>119</volume><issue>3</issue><year>2010</year><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1007/s10549-009-0666-9</pub-id><pub-id pub-id-type="pmid">20092022</pub-id></element-citation></ref><ref id="b0560"><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gaugler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mohty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malard</surname><given-names>F.</given-names></name></person-group><article-title>Plasmacytoid dendritic cell biology and its role in immune-mediated diseases</article-title><source>Clin. Transl. Immunol.</source><volume>9</volume><issue>5</issue><year>2020</year><fpage>e1139</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cti2.1139</pub-id><pub-id pub-id-type="pmcid">PMC7248678</pub-id><pub-id pub-id-type="pmid">32489664</pub-id></element-citation></ref><ref id="b0565"><mixed-citation publication-type="other" id="h0565">Zheng, C.; Penghui, Y.; Yueqiang, D.; Xiliang, W.; Wei, W.; Deyan, L.; Zhongpeng, Z.; Li, X.; Xiao, G.,2011. Respiratory syncytial virosome vaccine and preparation method thereof. Chinese Patent 2011, CN102078606B.</mixed-citation></ref><ref id="b0570"><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name name-style="western"><surname>Zurbriggen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name></person-group><article-title>Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice</article-title><source>Vaccine</source><volume>17</volume><issue>11&#8211;12</issue><year>1999</year><fpage>1301</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/s0264-410x(98)00361-2</pub-id><pub-id pub-id-type="pmid">10195764</pub-id></element-citation></ref><ref id="b0575"><mixed-citation publication-type="other" id="h0575">Zurbriggen, R.; Amacker, M.; Rasi, S.,2013. (a) Lyophilization of virosomes. Canadian Patent, CA2592437C</mixed-citation></ref><ref id="b0580"><mixed-citation publication-type="other" id="h0580">Zurbriggen, R.; Moser, C.; Kammer, A.; Amacker, M.; Westerfeld, N.; Rasi, S., 2013. (b) Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof. US Patent , US8367077B2.</mixed-citation></ref></ref-list><ack id="ak005"><title>Acknowledgement</title><p id="p0230">The authors extend their appreciation to the Deputyship for Research &amp; Innovation, Ministry of Education in Saudi Arabia for funding this Research work through the project number ISP22-16.</p></ack></back></article></pmc-articleset>